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ABSTRACT
Background: Timing of surgery signifies a decision of fundamental importance for 
the vascular patient whether with symptomatic carotid stenosis, a diabetic foot ul-
cer (DFU) or an abdominal aortic aneurysm (AAA). In general, all elective proce-
dures should take place in time to prevent the condition from progressing beyond 
the treatment possibilities. For the vascular patients in question, the obvious goals 
are: to operate on patients with symptomatic carotid stenosis before major stroke, to 
revascularise the limbs of patients with DFUs before amputation is required and to 
operate patients with AAAs before aneurysm rupture.  
Carotid surgery is the one area in vascular surgery where guidelines for the timing 
of surgery have been established even if the optimal time for surgery remains unclear. 
For symptomatic carotid stenosis, the risk of ischaemic stroke is the highest in the two 
weeks following the ischaemic symptoms and carotid surgery is hence recommended 
within the two weeks, a goal achieved for only 11% of the patients at Helsinki Uni-
versity Hospital (HUH) during 2007–2008. 
For patients with diabetic foot ulcers, the optimal timing of revascularisation based 
on the current literature is unclear.
Furthermore, based on available data, the optimal timing, i.e. the acceptable delay 
of elective AAA repair, is yet to be defined, and whether to treat certain patients at 
all remains unresolved. 
Aim of the study: The aim of this study was to investigate the timing of treatment and 
the concurrent impact on the outcome in the three major patient cohorts of vascular 
surgery: patients with symptomatic carotid stenosis, diabetic foot ulcers and large 
abdominal aortic aneurysms. 
Patients and methods: The study consisted of patients referred to elective surgical 
evaluation for symptomatic carotid stenosis in 2010, for DFUs in 2010–2011 and 
for large AAAs in 2000–2010. The patient cohorts were all retrospectively analysed, 
focusing on the timing of treatment and possible causes for delay. The outcomes of 
our elective treatment processes were also analysed with the main interest in the con-
sequences arising from a delay.
Main Results: For carotid surgery, the organisational changes made in 2009 resulted 
in 37% of the symptomatic patients being treated within two weeks, and the median 
time from symptom to surgery shortened from 47 (3–368) to 19 (1–236) days.  In 
the treatment of diabetic foot ulcers, a delay of more than two weeks from referral 
to revascularisation was associated with inferior limb salvage. The elective treatment 
Abstract
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process of AAAs comprised 21 (5.8%) emergency operations and 11 (3.0%) aneurysm 
ruptures. Of the patients excluded from surgical treatment, 33 % died of an aneurysm 
rupture, and 5 out of 12 patients undergoing an emergency operation survived.
Conclusions:  In carotid surgery, reaching the two-week target time is an achievable 
goal, provided that, in addition to the institutional changes, efforts are also made to 
improve public awareness.  
Diabetic foot ulcers always require diagnostics to detect the possible underlying 
ischaemia and rapid revascularisation once ischaemia is detected.
Guidelines for the timing of the elective AAA treatment process are important in 
order to minimise the amount of aneurysm ruptures and emergency operations that 
occur while waiting for surgery. Exclusion from elective aortic repair is a decision re-
quiring careful consideration and collaboration between different specialities. 
Causes and consequenses of delay in vascular surgery
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INTRODUCTION
The timing of surgery is important in vascular surgery, as delaying treatment jeopardises 
the future of the patient, with potential irreversible outcomes described for the three 
major vascular patient groups as follows: stroke for patients with symptomatic carotid 
stenosis, amputation for patients with DFUs and death due to aneurysm rupture for 
patients with AAAs. 
In carotid surgery, the aim is to reduce the risk of stroke after a cerebrovascular event, 
i.e. to maintain the current condition. Guidelines for the timing of surgery have been es-
tablished by Rothwell et al. (2004) based on data derived from large randomised trials, the 
North American Symptomatic Carotid Endarterectomy Trial and the European Carotid 
Surgery Trial. Rothwell and collaborators concluded carotid endarterectomy (CEA) to 
be highly beneficial in patients with symptomatic stenosis of over 50% when the patient 
undergoes an operation within two weeks from the ischaemic symptom. According to an 
observational study by Vikatmaa et al. (2011), only 11 % of patients with symptomatic 
carotid stenosis were treated within two weeks in Helsinki University Hospital (HUH), 
and the median time from symptom to surgery was 47 (3–368) days, heavily affected 
by the 25 (2–202) days of surgical delay, i.e. the time between consultation and surgery. 
For patients with DFUs, the optimal timing of treatment has not been defined. The 
aim of treatment for DFUs differs from carotid surgery, for the aim is in achieving wound 
healing in order to sustain limb salvage. A DFU affects approximately 25% of the patients 
with diabetes in their lifetime (Gregg et al. 2004). Of these ulcers 50%–60% have been 
considered to be of ischaemic origin (Prompers et al. 2008). With the increasing numbers 
of patients with diabetes worldwide, this signifies a growing burden on the healthcare 
system, Finland included (King et al. 1998). Defining the optimal timing of revascu-
larisation once ischaemia is detected presents a challenge, for it is ethically problematic 
to investigate delay prospectively. Therefore, conclusions are bound to be drawn from 
retrospective analyses and observational studies and treatment policies today are mainly 
based on practical experience. 
For patients with AAAs meeting the generally excepted treatment criteria of an an-
eurysm diameter of >55 mm, the aim of treatment is to avoid aneurysm rupture. The risk 
of rupture is related to the size of the aneurysm. According to Lederle et al. (2002), the 
annual rupture risk is 9.4% for aneurysms of 55–59 mm in size, 10.2% for aneurysms of 
60-69 mm and 32.5% for aneurysms of >70 mm. These estimations, however, are direc-
tional as the data is based on the surveillance of patients excluded from surgical treatment. 
The rupture data is, for the most part, extracted from death certificates without an autopsy 
confirming the finding, for the autopsy rate worldwide is in steep decline (Pompilio et 
al. 2008). Especially when a person is found deceased, pronouncing the cause of death 
without autopsy leaves plenty of room for speculation.
Introduction
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The timing of elective aortic surgery is based on estimations of the risk of rupture, 
and the aim is hence to treat larger aneurysms sooner; in HUH, the target time for the 
surgical delay, i.e. from decision on operative treatment to surgery, has been less than 
one month for aneurysms of > 65mm and 3 months for smaller aneurysms. Before the 
decision is reached, additional diagnostic imaging might be needed and the patient’s 
overall health and the perioperative risks need to be evaluated. These processes may 
take time and delay surgery further.  
Causes and consequenses of delay in vascular surgery
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REVIEW OF THE LITERATURE 
1 CAROTID SURGERY
1.1 INDICATIONS FOR SURGERY
1.1.1 Symptomatic stenosis 
The most important indication for carotid surgery is symptomatic internal carotid 
artery (ICA) stenosis, which is a stenosis detected after a cerebrovascular event; a 
transient ischaemic attack (TIA); amaurosis fugax (AFX); or stroke. Large-artery 
thrombosis accounts for 19%–21% of first strokes (Ward et al. 1988, O’Donnel et 
al. 2010), and carotid stenosis can be detected in 10%–16% of patients after a TIA 
or stroke (Kolominsky-Rabas et al. 2001, Poisson et al. 2011). All treatment aims at 
reducing the risk of future cerebrovascular events. So far the most important factor 
predicting the risk of a new cerebrovascular event is the degree of stenosis in ICA. 
Today’s guidelines are based on two large randomised trials, the North American 
Symptomatic Carotid Endarterectomy Trial (NASCET 1998) by Barnett et al. and 
the European Carotid Surgery Trial (ECST 1998) by the European Carotid Surgery 
Trialists’ Collaborative Group, which have provided the information on the benefits 
of surgery according to the degree of stenosis. After re-measurements to unify the 
definition of the stenosis degree and adjustment to obtain comparable results, the 
pooled analysis of these trials by Rothwell et al. (2003) revealed that carotid endar-
terectomy (CEA) is highly beneficial in symptomatic patients with a stenosis degree 
of 70%–99% and moderately beneficial with a stenosis degree 50%–69%.  
1.1.2 Asymptomatic stenosis 
The benefit for the patient from operating on asymptomatic stenoses continues to be 
under debate. In North America, the randomised ACAS trial (Asymptomatic Carotid 
Atherosclerosis Study) showed a significantly lower risk of stroke or death for patients 
with stenosis of > 60% when compared with patients treated only medically – 5.1% 
and 11.0%, respectively (Executive committee for ACAS 1995). These results con-
tributed to the increase in operations on asymptomatic patients in North America, 
where 48% of leading experts would recommend CEAs for an asymptomatic patient 
in comparison to 28% of leading experts in Western Europe (Masuhr et al. 1998). In 
Review of the literature 
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2004, the international multicentre Asymptomatic Carotid Surgery Trial (ACST) 
published results pointing in a similar direction: at 5 years, the stroke risk was 6.4% 
for patients undergoing CEA with stenosis of >70% and 11.8% for their medically 
treated counterparts (Halliday et al.). These trials share the same flaws, patient selection 
being the first, since patients with higher perioperative risks were excluded from the 
studies. Also, the best medical treatment has changed with more effective antihyper-
tensive medications and new anti-platelets such as clopidogrel. Furthermore, statin 
medication was not in common use at the time of the studies, and it has been argued 
later that these results do not transfer as such to modern times. 
1.2 SURGICAL TREATMENT 
1.2.1 Carotid endarterectomy 
CEA is the gold standard in the treatment of symptomatic carotid artery stenosis. In 
the operation, carotid vessels are dissected carefully, applying a non-touch technique to 
the affected internal carotid artery to avoid disturbing the plaque causing the stenosis. 
Carotid arteries are clamped and, through longitudinal incision or using eversion 
technique, the affected intima is removed, i.e. endarterectomised. If a longitudinal 
incision is used, patch closure is recommended (Hobson et al. 2008, Liapis et al. 2009). 
Operating on the ICA and clamping it during the procedure leads to the constant 
presence of a risk of perioperative stroke or death, and this risk is what the expected 
benefit is weighed against. According to results from NASCET, ECST, ACAS and 
ACST, CEAs should be performed only in centres that carry a <6% perioperative risk 
of stroke or death for symptomatic stenosis and a <3% risk for asymptomatic stenosis. 
1.2.2 Stenting 
Carotid artery stenting (CAS) is an option to open surgery. Via a puncture site typical-
ly in the common femoral artery (CFA), a stent is introduced through a long sheath or 
guiding catheter to the ICA.  A protection device against distal embolisation is com-
monly used and recommended by guidelines (Hobson et al. 2008, Liapis et al. 2009). 
1.2.3 CEA vs. CAS 
Randomised studies, the ICSS (International Carotid Stenting Study) with 1713 
symptomatic patients and the CREST (Carotid Revascularization Endarterectomy 
vs. Stenting Trial) with 1321 symptomatic and 1181 asymptomatic patients, present-
ed CEA in 2010 as the safer choice since CAS was associated with a higher risk of 
perioperative stroke, whereas CEA carried a higher risk of perioperative myocardial 
infarction (Brott et al.). The 10-year results from ICSS by Bonatti et al. (2015) recog-
nise the higher immediate risk of perioperative stroke related to CAS, but determine 
both CAS and CEA to be beneficial and durable options. This fairly novel treatment 
method takes time to master; according to Smout et al. (2010), the learning curve 
Causes and consequenses of delay in vascular surgery
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is almost two years in an active centre before the complication rate of under 5 % is 
obtained. In the hope of improving techniques and advances in the materials, great 
expectations are cast on CAS. However, according to the literature, it seems that CEA 
is superior to CAS, a position reinforced by a recent systematic review on contem-
porary administrative dataset registries by Paraskevas et al. (2015).  In 13 of the 18 
registries (72%), the 30-day stroke or death risk after CAS for a symptomatic patient 
with an “average risk” of CEA exceeded the 6% limit set by American Heart Associ-
ation (AHA) and American Stroke Association (ASA) guidelines. CAS remains the 
alternative for patients with high perioperative risks and certain anatomical conditions 
such as hostile neck post radiation or previous surgery. 
1.3 CONSERVATIVE TREATMENT 
For all symptomatic as well as asymptomatic patients, operated or not, the best medical 
treatment (BMT) is recommended. It has been shown that even though asymptomatic 
stenosis carries a low annual risk for stroke of 1%, the annual cardiac and all-cause 
mortality is significantly higher, 3.3% and 5.2 %, respectively (Giannopoulos et al. 
2015). In long-term follow-up of up to 15.2 years, patients undergoing CEA had a 
4.4-fold risk of acute myocardial ischaemia compared with age- and sex-matched 
population controls (Nuotio et al.2015), hence the conservative treatment of cardi-
ovascular risk factors is essential, including anti-platelet, statin and antihypertensive 
treatment as well as smoking cessation. 
1.3.1 Anti-platelet treatment 
Aspirin reduces the risk of stroke and cardiovascular death with a dosage of 75–150mg 
per day (Antithrombotic Trialists’ Collaboration 2002) and is recommended as pri-
mary and secondary prevention by the European Stroke Organisation (ESO) and 
the AHA/ASA. If the cerebrovascular symptom occurs while a patient is on aspirin 
medication, the policy has been to combine aspirin with dipyramidol or change aspirin 
to clopidogrel, alterations that have been shown to be equally effective in preventing 
recurrent stroke (Sacco et al 2008). Two randomised trials, the CARESS in 2005 and 
the CLAIR in 2010, investigated the relation of aspirin and clopidogrel combined with 
asymptomatic microembolisation among patients with recently diagnosed symptomat-
ic cerebral or carotid artery stenosis and discovered that the combination of aspirin and 
clopidogrel is more effective than aspirin alone in reducing the microemboli (Markus 
et al., Wong et al.). This dual antiplatelet therapy is also showing clinically promising 
results, as was reported in the recently published prospective audit by Batchelder et al. 
(2015), with reduction of recurrent symptoms from 13% to 3% after implementing 
a strategy where clopidogrel was combined with aspirin at a TIA clinic immediately 
after intracranial haemorrhage had been ruled out and continued through and after 
the perioperative period. 
Review of the literature 
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1.3.2 Statins 
Statins are known to be effective in the prevention of cardiovascular events in large 
randomised trials such as the Scandinavian Simvastatin Survival Study (4S 1994) and 
the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID study group 
1998), which both also implied statin medication’s association to stroke risk reduction. 
This matter was addressed in the CARE (Cholesterol And Recurrent Events) study 
by Plehn et al. (1999), and pravastatin was determined effective in reducing stroke 
and TIA incidence after a myocardial infarction. In secondary prevention, statins 
have been shown to reduce the incidence of cerebrovascular events and mortality 
among patients undergoing CEA (McGirt et al. 2005). The SPARCL (The Stroke 
Prevention by Aggressive Reduction in Cholesterol) trial by Amarenco et al. (2006) 
established that atorvastatin 80 mg taken once a day following a stroke or TIA result-
ed in a reduction of the incidence of stroke or cardiovascular events, a finding that 
has led to the use of high-dose statins as secondary prevention in general practice. In 
primary stroke prevention, the role of statins has been controversial, even though the 
effect on cardiovascular events has been established. For patients with asymptomatic 
carotid stenosis gathered from the prospective ACES (Asymptomatic Carotid Em-
boli Study) trial and followed for 2 years, statins had no effect on reducing the risk 
of stroke or cardiac death (King et al. 2013). However, asymptomatic stenosis of > 
50% predisposes the patient for a high risk of atherosclerotic cardiovascular disease 
events within 10 years and, according to the guidelines by the American College of 
Cardiologists and the American Heart Association (ACC/AHA), statin medication 
is therefore recommended (Giannopoulos et al. 2015). 
1.3.3 Antihypertensive medication 
Hypertension is linked with cardiovascular and overall mortality, and according to 
the guidelines by the ESO, lowering blood pressure to 140/85 mmHg or below serves 
as primary prevention of stroke as well coronary events. As secondary prevention, an-
tihypertensive medication also has an important role in preventing stroke recurrence 
and hyperperfusion syndrome after CEA (Naylor et al. 2013). 
1.3.4 Smoking cessation 
Smoking is an independent risk factor for stroke, with a relative risk of 1.67. (Wolf et 
al. 1988, King et al. 2013). Smoking cessation reduces the risk significantly, bringing 
it down to the same level as for non-smokers in 1–5 years (O’Donnl et al. 2010, Wolf 
et el. 1988). All patients with carotid stenosis should be guided towards smoking 
cessation and offered supportive medication. 
Causes and consequenses of delay in vascular surgery
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1.4 TIMING OF SUGERY 
1.4.1 The Past 
In the 1980s, it was considered beneficial to wait for 6 weeks before surgery, especially 
if the onset symptom was stroke. This waiting period was deployed in the fear of a fatal 
complication, cerebral haemorrhage. The evidence base for this fear was, however, weak 
and based only on a few publications (Wylie 1964) at a time when diagnostics were 
performed without the imaging methods of today, namely computed tomography 
(CT) and magnetic resonance imaging (MRI). Even before the NASCET and ERCT 
trials, it was shown that the 6-week wait is pointless and CEA can be performed safely 
(Dosick 1985, Piotrowski 1990), but delayed surgery still remained in practice past 
the turn of the century.  
1.4.2 The Present 
In a further pooled subgroup analysis of NASCET and ECST by Rothwell et al. 
(2004), the timing of surgery was taken into account, and in both trials, the benefit of 
stroke risk reduction rapidly declined after two weeks from the last symptom to CEA. 
Since then, two weeks has been the widely adopted goal from symptom to surgery. 
Initially, the median times exceeded this goal markedly, with results like 82 days in the 
UK (Dellagrammaticas et al. 2007) and 48 days in Sweden ( Johansson et al. 2008). 
Various efforts have been made and the delay has dramatically decreased during the 
last decade – according to the national vascular registries, it has been reduced to 13 
days in the UK, 7 days in Sweden and 12 days in Denmark (UK National Vascular 
Registry, Swedvasc, Karbase). 
A notable issue is how the index symptom is defined. Some institutions determine 
the index symptom as the first symptom that results in an operation, whereas others 
conceive it as the last symptom before the operation, thus excluding the possible recur-
rent symptoms. Recurrent ischaemic symptoms are reported to occur in 3.1%–5.2% 
of patients within 2 days after the index symptom, increasing to up to 11.2% within 
2 weeks (Giles et al. 2007, Johansson et al. 2013). The difference in the definition of 
index symptom meant 4–8 more days in median delay according to the observational 
study by den Hartog et al. (2014), emphasising the importance of this definition when 
reporting and analysing delays.
The relatively high risk of recurrence has steered the discussion today towards 
operating even sooner, within in the first 48 hours. CEA has been shown to be safe 
during this hyperacute period, with a similar risk of stroke or death when compared to 
patients operated on in 2–14 days (Sharpe et al. 2013, Tsivgoulis et al. 2014). However, 
according to the Swedish vascular registry Swedvasc, the combined stroke or death rate 
was 11.5% for patients operated on within 2 days of the onset symptom as opposed 
to the stroke or death rate of 3.6%–4.0% among patients operated within 2–14 days 
and 5.4% for patients operated within 15–180 days. (Stromberg et al. 2012), so the 
matter of optimal timing remains under debate. 
Review of the literature 
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Expedited surgical treatment requires distinguishing the patients at the greatest risk 
of a recurrence of TIA or stroke. Clinical risk prediction tools have been established 
to help in this task, and the most commonly used one is the ABCD2 score ( Johnston 
et al. 2007, Ehsan et al. 2008), in which 1 point per character is gained from Age over 
60, Blood pressure above 140/90 mmHg, Clinical presentation of speech impairment, 
a Duration of 10–59 minutes and having Diabetes. Weakness of a unilateral limb 
adds 1 point and a duration of symptoms of over 60 minutes another. A score of >6 
points indicates high risk and <3 low risk. The sensitivity of the ABCD2 score has 
been questioned and demonstrated to be poor in a large meta-analysis by Wardlaw 
et al. (2015). By adding Dual events (recurrence of symptoms within 7 days) to the 
score with 2 points produces the ABCD3 score, which has been shown to be more 
accurate in predicting stroke risk but does not exclude the need for imaging studies 
(Purroy et al. 2012, Johansson et al. 2013). These imaging studies are also currently 
of great interest concerning carotid plaque morphology. An ulcerated plaque surface 
in an angiogram (Lovett et al. 2004) as well as the presence of intraplaque haemor-
rhage in MRI (Saam et al. 2013) have been associated with an increased risk of stroke 
recurrence. Positron emission tomography (PET) imaging has also yielded promising 
results on identifying the vulnerable plaques (Graebe et al. 2010, Pedersen et al. 2015). 
Hence, imaging may play a major role in the future in distinguishing the patients at 
highest risk of recurrent symptoms and stroke. 
1.4.3 Timing of carotid surgery in the Helsinki and Uusimaa 
region 
According to an observational study by Vikatmaa et al. (2011), in Helsinki University 
Hospital with catchment area of approximately 1.5 million inhabitants, the median 
delay from first symptom to surgery was 47 days in 2008, and only 11% of the patients 
were operated on within two weeks. A recurrence or progression of symptoms was 
experienced by 10% of the patients while waiting for CEA in a median of 8.5 days 
from the index symptom, and 40% had had recurrence or progression prior to hospital 
contact (Sairanen et al. 2012).  
1.5 GUIDELINES FOR THE TIMING OF SURGERY
Both the European Society for Vascular Surgery (ESVS) in 2009 (Liapis et al.) and the 
Society for Vascular Surgery (SVS) in 2008 (Hobson et al.) have published guidelines 
for carotid interventions, with similar recommendations. For symptomatic patients 
with >50% stenosis, the recommended treatment is CEA. The ESVS guidelines state 
that the operation should take place within 2 weeks of the last symptom. The timing 
of surgery was not addressed in the SVS guidelines of 2008, but in the update (Ricotta 
et al. 2011), the timing is discussed and the conclusion is that a carotid intervention 
is preferably performed within 2 weeks rather than delayed until 4–6 weeks.
Neurologists have also taken a stand concerning the timing of surgery. The ESO 
established in their guidelines (ESO executive committee 2008) for the management 
Causes and consequenses of delay in vascular surgery
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of ischaemic stroke and transient ischaemic attack that CEA should be performed 
as soon as possible, preferably within 2 weeks from the last symptom, and the same 
position was taken by the AHA/ASA guidelines: “surgery within 2 weeks is reason-
able rather than delaying surgery if there are no contraindications to early revascu-
larisation”(Brott et al. 2013). In the UK, the National Institute for Health and Care 
Excellence (NICE) have guidelines from 2008 also stating that a patient expressing 
TIA or stroke symptoms should undergo surgery within a maximum of 2 weeks, 
whereas the UK National Stroke Strategy by the Department of Health has taken a 
more active position and recommends a carotid intervention for high-risk patients 
(ABCD >4) within 48 hours. 
1.6 DELAY IN THE TREATMENT PROCESS 
1.6.1 Pre-hospital delay
1.6.1.1 Patient-related delay 
A patient-related delay is the time from the symptom until the patient seeks help 
from a health care professional. The countdown for the delay starts with the patient’s 
reaction to the onset of symptoms. The awareness of the need for urgent evaluation of 
ischaemic cerebral symptoms remains relatively low (Parahoo et al. 2003, Dombrowski 
et al. 2015, Ntaios et al. 2015), and even if the symptoms are recognised, the willing-
ness to seek help immediately often seems to be lacking. By-standers (family, friends 
or passers-by) have an important role in the first crucial minutes when the course is 
set for the treatment process (Mellor et al. 2015, Wolters et al. 2015). Several ways 
to improve public awareness have been introduced ranging from printed materials, 
lectures and courses to the use of mass media (Martin 2014). The mass media reaches 
the largest amount of the population, and significant results have been achieved after 
such campaigns in raising public awareness, but the effect on publics behaviour has 
remained meagre (Marx et al. 2008, Hartigan et al. 2014). One of the largest cam-
paigns using television with promising results is the FAST (face-arm-speech-time) 
campaign, which educates the public about the alarm symptoms (face-arm-speech), 
in addition to encouraging people to act quickly (time) and call for help immediately 
(Flynn et al. 2014). This campaign, first launched in the US (Kleindorfer et al. 2007), is 
currently in use in several countries. In the UK, after a television campaign, the median 
time to seeking attention fell from 53 to 31 minutes and the median time to hospital 
arrival from 185 to 119 minutes (Wolters et al.2015). In Japan, after a FAST-based 
TV campaign, the pre-hospital delay fell from a median of 13.5 hours to 12 hours 
and the proportion of patients arriving within 3 hours of the symptoms rose from 
46.5% to 55.7% (Nishijima et al. 2015).  It is one thing to raise public awareness, but 
quite another to maintain the knowledge. The effect of awareness campaigns seems 
to fade in 5 months, and continuous campaigning is therefore needed in order to 
uphold public awareness (Hodgson et al. 2007).
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1.6.1.2 Referral delay  
Referral delay is the time from the patient’s first healthcare contact to the evaluation 
by a neurologist or vascular surgeon. The first health care contact is often a general 
practitioner (GP) (Vikatmaa et al. 2011). According to a Swiss questionnaire study, 
the referring GPs seemed to have a fairly good perception of the importance of TIA 
symptoms to the risk of stroke, even to the point of overestimation, but many of them 
still did not consider emergency referral necessary if encountered by a TIA patient 
(Streit et al. 2015).
The foundation of TIA clinics has played an important role in shortening referral 
delay, making the first contact and evaluation possible in 24 hours (Lavallee et al. 
2007,Rothwell et al. 2007, Salem et al. 2011). Even though it has been reported that 
50% of patients referred are in fact TIA mimics, the effect on stroke risk reduction 
is still evident, with a decline in reported stroke risks at 90 days from 7.5%–9.4% to 
1.3%–2.9% after the implementation of TIA clinics (Dutta et al. 2015).
1.6.2 In-hospital delay
1.6.2.1 Imaging delay 
Imaging delay is the time it takes to image the carotid arteries. Imaging is rarely delayed 
if the previous steps of the treatment process have gone fluently and the patient arrives 
on an emergency basis to a centre where immediate diagnostics and care are available. 
Computed tomography (CT) is widely available around the clock and therefore 
used as the first imaging method with the advantage of fast imaging and the possible 
inclusion of imaging the carotid vessels. Magnetic resonance imaging (MRI) has been 
shown to be more accurate in detecting small ischaemic lesions after a TIA or minor 
stroke (Moreau et al.  2013, Sidorov et al. 2014), and if availability will increase in 
future, MRI could replace CT as the first-line imaging study.
1.6.2.2 Neurological delay 
The delay from evaluation by a neurologist to vascular surgeon is usually not the 
problem, since the need for surgery is usually established at this point and a vascular 
surgeon consulted accordingly. The patient’s overall condition may delay the consul-
tation, which bears little relevance, however, since the patient in such a case is usually 
not fit for surgery. In Helsinki, the neurological delay was a median of 7 days, including 
the imaging studies (Vikatmaa et al 2011).
1.6.2.3 Surgical delay 
Surgical delay is the time from the decision to operate until the operation takes place. 
When the decision on CEA is reached, the goal for the vascular surgeon is to schedule 
the operation within two weeks from the index symptom, which is possible only if the 
two weeks has not already passed. Surgical delay has contributed considerably to the 
delay from symptom to surgery in the earlier reports, and reducing this component 
has also shortened the overall delays remarkably. ( Johansson et al. 2008, den Hartog 
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et al. 2014) The long median delay of 47 days from symptom to surgery in Helsinki 
was also heavily influenced by the surgical delay of median 25 days (Vikatmaa et al. 
2011). Reducing the surgical delay as well as other elements of in-hospital delays is 
more easily achieved than the reduction of the pre-hospital delay, but it does require 
resources to achieve, mainly operating hours and the accessibility of an operating 
room on an emergency basis if needed.
2 DIABETIC FOOT ULCERS
2.1 INCIDENCE AND PREVALENCE OF DFUS
The prevalence of diabetes is on the rise from an estimated 284 million worldwide in 
2010 to up to 439 million or even more by the year 2030 (Shaw et al.2009, Danaei et 
al. 2011). In Finland, approximately 400 000 patients had diagnosed diabetes in 2007 
according to Ikonen et al. (2010). With undiagnosed patients included, the number 
of patients with diabetes has been suggested to rise to up to almost 1 million in the 
next decade (Sund et al. 2009).
Foot ulcerations affect up to 25% of patients with diabetes in their lifetime (Gregg 
et al. 2004, Singh et al. 2006) – therefore, in Finland, we can expect close to a quarter 
of a million diabetic foot ulcers (DFUs) in the future. 
2.2 DEVELOPMENT OF DFU
The formation of a DFU is a multifactorial process, most often including neuropathy, 
deformity and trauma (Reiber et al. 1999). Diabetic peripheral neuropathy (DPN) 
embodies sensorial, motor and autonomic sympathetic components. The clinical 
findings are loss of sensation in a stocking-like distribution, small muscle loss and joint 
immobility, deformities like claw toes and hallux valgus as well as reduced sweating, 
which can lead to dry skin and callus formation (Bowling et al. 2015). For the majority 
of the patients, DPN commences the pathway to ulcer formation; sensory loss leads to 
the absence of pain as a warning signal, while small muscle loss and joint immobility 
predispose to deformity and altered pressure distribution, all of which combined with 
callus formation easily result in an ulcer after minor trauma. 
2.3 DIABETIC FOOT AND PAD
Peripheral artery disease (PAD) affects 9%–23% of patients with diabetes and, accord-
ing to the prospective Eurodiale study, ischaemia is present in 50%–60% of DFUs, 
raising the annual major amputation and mortality rate from 2% to 8% and from 3% 
to 9%, respectively (Prompers et al. 2007,2008). The manifestation of PAD in diabetes 
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has distinctive features; mainly the infra-popliteal arteries are affected diffusely and, 
in the artery wall, the sclerosis affects the tunica media rather than the intima (Faglia 
et al. 1998). The profunda femoris artery has also been shown to present with worse 
disease compared to patients with no diabetes ( Jude et al.2001).  
2.3.1 Investigations for PAD in patients with diabetes 
All DFUs should be evaluated for the presence of PAD, starting with the palpation 
of the pedal pulses. Palpable pulses are considered a sign of adequate blood flow. 
However, palpation findings have been shown to be unreliable (Lundin et al. 1999) 
and, on the other hand, the presence of pedal pulses does not conclusively exclude 
PAD (Rivers et al. 1990, Collins et al. 2006). Ankle Brachial Index (ABI) measure-
ment is in routine use for detecting ischaemia, though for patients with diabetes it 
has been proven to be directional at best due to medial sclerosis (Aerden et al. 2011, 
Alvaro-Afonso et al. 2015). Further information may be gained from toe pressure (TP) 
and transcutaneous oxygen pressure (TcPO2) measurements, which have demonstrat-
ed superior reliability in the examination of patients with diabetes (Brownrigg et al. 
2015, Sonter et al. 2015). 
A systematic review of the effectiveness of bedside investigations was recently 
conducted by the International Working Group on the Diabetic Foot (IWGDF), 
with a conclusion of insufficient evidence to support a single non-invasive diagnos-
tic modality for the detection of PAD among patients with diabetes (Brownrigg et 
al. 2015). Therefore, in the case of DFU, regardless of the measurements, imaging 
to determine the anatomical distribution of the disease should be performed if any 
doubt concerning blood supply to the ulcerated foot exists. The imaging methods 
most often used today are magnetic resonance angiography (MRA) and computed 
tomography angiography (CTA) instead of digital subtraction angiography (DSA), 
with the advantage of non-invasiveness and better availability for CTA and avoidance 
of iodinated contrast and radiation exposure for MRA (Meyersohn et al. 2015). 
Doppler ultrasound scanning can also be used and is undoubtedly the least-invasive 
imaging method, but it can be time-consuming and requires a skilled professional to 
obtain reliable and DSA-comparable results, especially on the crural arteries (Eiberg 
et al. 2010).  
2.4 FACTORS INFLUENCING THE OUTCOME OF DFU 
2.4.1 Renal function 
Impaired renal function complicates the diagnostics and treatment of DFUs, as iodinated 
contrast is not recommended in patients who still have some renal function left. Patients 
with end-stage renal disease (ESRD), on the other hand, can undergo these procedures as 
long as they attend dialysis afterwards. Diabetic nephropathy is the leading cause of ESRD 
and dialysis treatment (Bjornstad et al. 2015). ESRD is also a risk factor for the development 
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of DFU (Lewis et al. 2012), and it has a negative effect on ulcer healing and is associated 
with a higher risk of limb loss and mortality (Ndip et al. 2010, Lepäntalo et al. 2012). 
2.4.2 Wound characteristics 
Diabetic ulcers are very heterogeneous, ranging from superficial abrasions with good 
healing potential to bone penetrating infectious ulcers needing surgical revision and 
to gangrene a step away from amputation, hence the expectations for wound healing 
are bound to vary also. 
2.4.2.1 Wound classifications 
Classification systems for wound characteristics have been established in order to pre-
dict the outcome of DFUs. In 1976, the Meggit classification was first introduced, but 
it was taken into wider use in 1981 after reintroduced by Wagner. This Wagner-Meggitt 
classification disregards possible infection and ischaemia and categorises the wounds 
by depth in 6 grades (0–5) from pre- or post-ulcerative lesion to whole foot gangrene. 
In 1996, Lavery et al. presented the University of Texas wound classification (Table 1), 
which includes the evaluation of ischaemia and infection and is therefore considered 
more applicable in estimating DFUs (Oyibo et al. 2001).
Table 1	 The	University	of	Texas	Wound	classification	modified	from	Lavery	et	al.1996	
with	permission.
More recently, wound classifications have been developed with further consideration 
also for ulcer area and neuropathy, such as the classifications S(AD)SAD (Size [Area, 
Depth], Sepsis, Arteriopathy, Denervation) and the PEDIS  (Perfusion, Extent, Depth, 
Infection and Sensation) by IWGDF, both showing promising results (Treece et al. 
2014, Chuang et al. 2015), but none of  these classifications have proven to be com-
pletely adequate; for example, the degree of ischaemia is not defined in detail and 
the inter-observer agreement grading the classifications is demonstrated to be only 
moderate (Santema et al. 2015).
The Society for Vascular Surgery (SVS) introduced in 2014 the WIfI (Wound, 
Ischemia, foot Infection) classification (Mills et al. 2014), which takes into account 
the severity of ischaemia according to ABI, TP or TcpO2 and estimates the risk of 
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amputation at 1 year in four clinical categories ranging from very low risk to high 
risk of amputation (Table 2). The correlation of the classification system with wound 
healing and limb salvage has been validated, but further efforts are still needed in 
order to incorporate this classification into wider clinical use (Cull et al. 2014, Zhan 
et al. 2015). The use of the same classification in common practice would simplify 
clinical work and enable the collection of comparable data, thus benefitting both the 




2.4.2.2 Wound location 
The location of the ulcer has not conclusively been shown to affect wound healing 
(Ince et al. 2007), but higher recurrence rates for ulcers on the plantar surface have 
been reported (Dubsky et al. 2013). On the other hand, a recent large cohort study by 
Örneholm et al. (2015) consisting of 701 patients with plantar ulcers demonstrated 
a 79% healing rate in a median of 17 weeks. The location of the wound can be cate-
gorised according to the angiosome concept, which has been used in plastic surgery 
ever since it was first introduced by Taylor and Palmer in 1987. Vascular surgeons 
became interested in the concept after Attinger et al. (2006) presented the concept 
with the division of the foot and ankle area into 6 angiosomes according to the artery 
supplying vascularisation. The major flaw with the angiosome concept, however, is the 
fact that there is often more than one ulcer and the ulcer, or ulcers, is rarely located in 
only one angiosome area. In a recent study by Spillerova et al. (2015) on 161 patients 
(66.5% with diabetes) with critical limb ischaemia and a foot ulcers, only 24% of the 
ulcers were located in one angiosome. 
2.4.3 Previous ulcer or minor amputation 
Of all the risk factors for DFUs, a previous ulcer or amputation is the most predictive 
(Boulton 2004, Monteiro-Soares et al. 2012). After a minor amputation, the greatest 
risk of further amputation is in the first six months (Izumi et al. 2006).
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2.5 TREATMENT  
2.5.1 Preventive methods  
The prevention of ulcer formation is pivotal in the treatment of diabetes. Repeated 
education in foot care and guidance in daily foot inspections should be provided 
for all patients with diabetes (Schaper et al. 2015).  The recommendation is general 
knowledge among health care professionals, but awareness among patients with diabe-
tes worldwide remains insufficient (Basu et al. 2004, Saurabh et al. 2014, Lamchahab 
et al. 2011). 
In 2010, Lavery et al. demonstrated in two high-risk patient cohorts of diabetic 
patients in dialysis and patients with previous DFUs that only 1.3% of the patients 
received formal education and 30% preventive podiatric care.  Well-fitting shoes are 
an important factor in ulcer prevention as ill-fitting shoes have been shown to be 
associated with a 29% causality for ulcer formation (Connolly et al. 2004). Connolly 
et al. (2004) also showed in a study of 200 male veterans visiting a podiatry clinic 
that the shoe size increased by at least 1 shoe size in 48% of the study patients during 
adulthood, a plausible risk factor for ulcer formation. They recommend controlling 
the shoe size regularly after the age of 50 years.
The IWGDF recommends the evaluation of diabetic feet annually by a healthcare 
professional. This evaluation should include the palpation of pedal pulses, a sensory 
examination with monofilament from the plantar surface and with a tuning fork from 
the dorsal side of the distal phalanx of the first toe. (Hinchcliffe et al. 2015.)
2.5.2 Conservative treatment 
All cardiovascular risk factors worsen the outcome of DFUs, and, therefore, smoking 
cessation, which is also an independent risk factor of ulcer formation and gangrene 
(Al-Rubeaan et al. 2015), as well as the control of hypertension and dyslipidemia 
along with adequate treatment of diabetes are the basis of conservative treatment 
(Heikkinen et al. 2007). Medical treatment usually includes anti-platelet therapy, 
even though lower effects in patients with diabetes have been reported for the two 
most commonly used drugs, aspirin (Sacco et al. 2003, Watala et al. 2004) and clopi-
dogrel (Angiolillo et al. 2005). The diminished anti-platelet activity is suggested to 
be influenced by dyslipidemia, for which statin treatment is nearly always initiated. 
The beneficial role of statin use in patients with diabetes has shifted from being a 
hypothesis (Gulcan et al. 2007) to reducing the risk of major amputation (Sohn et al. 
2013) and, when combined with angiotensin-converting enzyme (ACE) inhibitors, 
mortality as well (Faglia et al. 2014).
Of other medications, iloprost has been suggested as being beneficial in wound 
healing for DFUs (Altstaedt et al. 1993), but according to a Cochrane review (Ruf-
folo et al. 2010) based on 20 eligible trials out of 111 potential ones, no conclusive 
evidence exists for the long-term effectiveness and safety of different prostanoids, 
even if some positive results concerning rest-pain relief, ulcer healing and amputations 
have been achieved.  
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2.5.3 Revascularisation 
After ischaemia is detected and arterial imaging performed, the revascularisation 
strategy is selected as either endovascular treatment (ET) or open surgery (OS) ac-
cording to the findings of the imaging study. Traditionally, long total occlusions are 
considered best-suited for bypass surgery and shorter lesions for ET, but with evolving 
materials and methods, ET has become more applicable, shifting the balance within 
the last decade towards most patients undergoing endovascular treatment. (Skrepenk 
et al. 2013.) The outcomes of both strategies are of great interest and have been widely 
investigated, but legitimate results are scarce mainly due to the diversity of clinical 
features of the patients with DFUs and the versatile manifestations of the arterial 
disease, making the standardisation of study patients nearly impossible. 
2.5.3.1 Endovascular Treatment (ET) 
Endovascular treatment is usually performed via an antegrade puncture in the common 
femoral artery (CFA) or the superficial femoral artery (SFA) as the target lesions in 
patients with diabetes are mainly below the knee. Faglia et al. (2002) demonstrated 
in their multicentre study consisting of 219 patients with DFUs infrapopliteal an-
gioplasty to be feasible and safe with an 87.2% technical success rate, with one case of 
temporary renal failure managed medically as the only complication. The limb salvage 
rate during a median of 12 months’ follow-up was 94.8%. According to DeRubertis 
et al. (2008), limb salvage after ET is similar in patients with and without diabetes, 
but primary patency at one year is inferior in diabetics. The study, however, included 
patients with indications for treatment varying from claudication to limb-threatening 
ulcers, and the latter were significantly more common among patients with diabetes 
(p< 0.004), thus rendering the relevance of the finding questionable.
The majority of endovascular procedures performed for DFUs include the re-
canalisation of the stenosis or occlusion and balloon angioplasty, i.e. percutaneous 
transluminal angioplasty (PTA). Stents have been used only if absolutely necessary 
as a bail-out alternative (Randon et al. 2010); today, however, drug-coated stents are 
also an option, with some promising results (Antoniou et al. 2013, Fusaro et al. 2013). 
Drug-eluting balloons (DEB) are also of great interest currently – in a randomised 
trial comparing below-the-knee paclitaxel-coated DEBs to conventional PTA among 
diabetic patients with critical limb ischaemia, Liistro et. al. (2013) demonstrated re-
duced rates of restenosis, target lesion revascularisation and target vessel occlusion at 
one year. The second study with the same DEB, the IN.PACT Amphirion, however, 
resulted in the withdrawal of the device from the market at 12 months due to a trend 
(non-significant) towards an increased major amputation rate among the patients 
treated with the DEB (Zeller et al. 2014). Further studies are therefore needed, but, 
potentially, these novel methods are the methods of the future ( Jaff et al. 2015). 
In a retrospective study by Acin et al. (2014), 101 infrapopliteal endovascular proce-
dures were performed for diabetic feet with ulcers. The ulcer healing rate at one year was 
55.0%, reflecting the slow healing process, while the limb salvage rate at two years was still 
74.9% and amputation-free survival 63.3%, results that can be considered to be fairly good.
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Restenosis is common after infrapopliteal ET, and several procedures are often 
needed to achieve wound healing and limb salvage. The re-intervention rate has been 
reported to be 5%–26% (Faglia et. al 2002, Giles et al. 2008, Fossaceca et. 2013, 
Söderström et al. 2013).
2.5.3.2 Open Surgery (OS) 
Open surgery is selected when endovascular treatment is expected to fail or has already 
failed, and the treatment plan is usually bypass to the crural or pedal arteries, since 
the affected arteries are mainly below the knee. 
The outcome of bypass surgery in patients with diabetes has previously been con-
sidered to be inferior compared to patients with no diabetes. Virkkunen et al. (2004) 
demonstrated in the Finnvasc study with 5709 patients undergoing surgery for critical 
limb ischaemia that diabetes is an independent risk factor for below-knee amputation 
(OR 1.7), cardiac complications (OR 1.5) and wound infection (OR 1.3). Diabetes 
was also associated with major cardiac events (OR 2.5) in a study by Roghi et al. 
(2001). Furthermore, in a retrospective review by Wallaert et al. (2012), diabetes was 
found to be a significant contributor to the risk of postoperative complications after 
bypass surgery. Insulin dependence was associated with higher risk. The comorbidities 
of patients with diabetes therefore require special attention when invasive interven-
tions are planned. The results of the revascularisation, on the other hand, have been 
shown to be equal after bypass surgery concerning graft patency and limb salvage 
among patients with and without diabetes. (Schantzer et al. 2008, Oberhuber et al. 
2013.) . 
2.5.3.3 Endo vs. open 
The “endovascular first” approach has gained a strong foothold in today’s practice, with 
several studies advocating the strategy (Arvela et al. 2011, Garg et al. 2014, May et al. 
2014, Katib et al. 2015). Therefore, OS is performed on many after failed ET. Contra-
dictory results from secondary bypass surgery have been reported; a study by Uhl et al. 
(2014) determined no negative effect on the outcome of patients undergoing pedal bypass 
surgery after failed ET, whereas Nolan et al. (2011) described higher amputation and 
graft occlusion rates at one year for bypasses after ipsilateral PTA. Other reports have also 
emerged in opposition to the “endovascular first” strategy – Spinelli et al. 2015 reported 
significantly inferior limb salvage rates at 1 month and 1 year among patients undergoing 
bypass surgery after failed ET. In a study by Jones et al. (2013) comparing 1154 patients 
undergoing secondary bypass surgery with 2350 patients undergoing primary surgery, the 
freedom from major adverse limb events was significantly inferior in patients undergoing 
secondary surgery after primary endovascular treatment but also after prior surgery, em-
phasising the importance of the first revascularisation plan. Most reports, pro and con, 
have assumed a similar perspective on the entire endo vs. open debate to rather disregard 
the confrontational set up altogether and focus on the individual needs of the patient 
with an optimised treatment process including a tailored revascularisation plan accord-
ing to the vascular morphology (Dick et al. 2007, Garg et al. 2014, Spinelli et al. 2015).
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2.5.3.4 Angiosome-targeted revascularisation  
In the analyses of wound healing, the angiosome concept is currently often taken 
into account and the comparison is made between direct revascularisation (DR) and 
indirect revascularisation (IR), describing the achieved blood flow to the angiosome 
of the ulcer. In a systematic review and meta-analysis of 15 studies comparing these 
approaches, DR was associated with improved wound healing and limb salvage, but no 
difference was found in mortality or re-intervention rates (Bosanquet et al. 2014). One 
of the fifteen studies included in the review was conducted in HUH by Söderström 
et al. (2013) on 250 consecutive diabetic feet with ulcers undergoing infra-popliteal 
PTA, with significantly better (p<0.001) wound healing after DR (72%) than IR 
(45%). In a study by Spillerova et al. (2015) on 744 consecutive patients undergoing 
any infra-popliteal revascularisation, DR was also found superior in regard to wound 
healing and limb salvage, but bypass surgery surpassed ET in wound healing even if 
performed indirectly. The importance of an intact pedal arch might partly explain 
the finding, for it has been shown to be more important as regards wound healing 
in bypass surgery than the direct angiosome revascularisation (Rashid et al. 2013). 
The aim according to the IWGDF guidelines is to restore direct flow to at least one 
of the foot arteries, preferably the artery supplying the area of the ulcer (Hinchcliffe 
et al. 2015), i.e. angiosome-targeted revascularisation is recommended. This aim, 
however, is jeopardised by the fact that there is rarely a choice between DR and IR, 
but rather revascularisation is performed at the site possible.  
2.5.4 Topical treatment 
There are numerous topical agents and dressings on the market for the treatment of 
DFUs. Reliable and unbiased data is hard to come by as the products are constantly 
evolving. No superiority has been determined in favour of certain topical agents ( Jude 
et al. 2007, Jeffcoate et al. 2009, Dumville et al. 2013).
The effectiveness of hyperbaric oxygen therapy on wound healing was evaluated 
in a recent Cochrane review (Kranke et al. 2015), with ten out of the twelve studies 
included focusing on diabetic feet. Short-term wound healing was improved, but no 
long-term effect on wound healing was seen and the impact on limb salvage remains 
unclear.
The strongest, though not conclusive, evidence seems to be for the positive effect 
of negative pressure wound therapy in assisting wound closure and limb salvage (Lav-
ery et al. 2007, Garwood et al. 2015, Hasan et al. 2015), and this therapy method is 
widely utilised today.
Topically applied growth factors are being studied in prospective randomised 
settings, and promising results have been reported on connective tissue growth factor 
(Henshaw et al. 2015), whereas platelet-derived growth factor does not seem to 
improve the healing of DFUs (Ma et al. 2015). Further studies in order to substantiate 
the role of growth factors are needed. 
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2.6 GUIDELINES ON THE TIMING OF REVASCULARISATION
2.6.1 IWGDF 
The International Working Group on the Diabetic Foot was established in 1996, and 
the latest recommendations for the prevention and management of diabetic foot were 
established in 2015. Evaluation for the presence of PAD is recommended for all DFUs 
by measuring ABI and TP, and TCPo2 may also be used. Urgent imaging should be 
considered with an ABI of < 0.5, ankle pressure of < 50mmHg, TP of < 30mmHg 
or a TcPo2 of < 25 mmHg.  If the DFU does not show improvement within 6 weeks, 
vascular imaging needs to be considered irrespective of the measurement results.
2.6.2 Finnish guidelines
The Finnish Current Care guidelines from 2009 and the update from 2013 are in 
accordance with the IWGDF guidance, also including recommendations for the 
urgency of the referrals from primary care. All ischaemic DFUs should be referred 
for vascular investigations, with the aim of 1–8 days. Emergency referral should be 
written for patients with an infectious DFU and systemic symptoms regardless of 
the presence of ischaemia.  
2.7 DELAY IN THE TREATMENT PROCESS 
2.7.1 Patient-related delay 
As discussed earlier, the prevention of ulcer formation is a priority in the treatment 
of DFUs, but when preventive methods fail and an ulcer appears, patient awareness 
defines the course that the ulcer treatment takes. Due to neuropathy, the detection of 
the wound may be delayed, and daily check-ups are therefore recommended. (Bus et 
al. 2015.) According to a cohort study on referral trajectories by Sanders et al. (2013), 
once an ulcer was detected, a median of 3 (0–243) days passed before the patient 
contacted a health care professional and a further 7 (0-279) days before a podiatrist 
was consulted.  In a retrospective study by Yan et al. (2013) on 270 patients with 
diabetic foot problems, the pre-hospital delay was a median of 46.5 days. The longest 
delays were independently associated with poor diabetic foot education and a lack of 
knowledge concerning foot lesion warning signs. 
2.7.2 Referral delay 
The delay between the first health care professional and an evaluation by a vascular 
surgeon when ischaemia is suspected has not been investigated; the previously men-
tioned 6 weeks of conservative treatment before considering vascular procedures is 
widely adopted as common practice.  
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2.7.3 Imaging delay 
The time it takes to have the necessary imaging carried out for the planning of the 
revascularisation may increase the delay and affect the outcome of the DFUs, but no 
data currently exists on this issue.  
2.7.4. Surgical delay 
For the time being, no guidelines have been established for the timing of non-urgent 
procedures. When a vascular surgeon first examines a DFU, a considerable amount 
of time has already passed. Due to this highly variable pre-hospital delay, determining 
the optimal time for revascularisation presents a challenging task, and no studies had 
previously addressed the issue. In a recent retrospective study by Elzgyri et al. (2014) 
on 478 ischaemic DFUs, the median time from first presentation at a multidisciplinary 
diabetic foot centre to revascularisation was 8 (3–18) weeks including imaging, which 
was conventional angiography during the study period of 1984–2006. A delay of less 
than 8 weeks was associated with a higher probability of healing.
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3 ABDOMINAL AORTIC ANEURYSMS 
3.1 PREVALENCE OF AAAS
The prevalence of abdominal aortic aneurysms (AAA) determined as an  enlargening 
of the aorta by over 30 mm has been reported to vary from 1.3% to 8.9% in men and 
from 1.0% to 2.2% in women (Sakalihasan et al. 2005, Zankl et al. 2007). The prev-
alence has changed in the recent decades according to data obtained from screening 
studies. When the Veterans Affairs Cooperative Study Group published the results of 
the Aneurysm Detection And Management (ADAM) trial, the overall prevalence of 
AAAs was 4.6% among the study population of 73,451 veterans and, after validation 
with a second cohort consisting of 52,745 veterans, 3.6% (Lederle et al. 1997 and 
2000). Also, in the Multicentre Aneurysm Screening Study (MASS), the prevalence 
among patients screened was 4.9% (Ashton et al. 2002), whereas in a recent study 
by Benson et al. (2015) on men participating in the National Abdominal Aortic 
Aneurysm Screening Program (NAAASP), the reported prevalence was only 1.18%.
3.2 RISK FACTORS FOR AAA
A well-known risk factor is male sex, as is evident in the difference in prevalence be-
tween the sexes. In a screening trial by Scott et al. (2002), an AAA was found in 1.3% 
of women and in 7.6% of men. Age is also a notable risk factor, for the prevalence of 
AAAs has been shown to increase after the age of 65 years from 2.7 % to 4.4% in ten 
years (Vardulaki et al. 2000). 
A family history of AAAs raises the risk of aneurysm formation. In a study focusing 
on the siblings of patients undergoing surgical aneurysm repair, the overall prevalence 
of AAAs was 6.1%, but for male siblings over 65 years of age, the prevalence was as 
high as 16.7% (Ogata et al. 2005).
In a systematic review by Cornuz et al. (2004), smoking, previous myocardial 
infarction and peripheral artery disease were all moderately associated and hyperten-
sion weakly associated with AAA, whereas in a more recent prospective cohort study 
including 18,782 patients, smoking was determined as the strongest risk factor, and 
myocardial infarction was negatively associated with AAA incidence ( Jahangir et al. 
2015). The role of smoking as the most significant risk factor for AAA is undisputed, 
but for hypertension and coronary artery disease (CAD), the association is not un-
equivocally substantiated. Blanchard et al. (2000) found both smoking and elevated 
diastolic pressure to be independent risk factors. Madaric et al. (2005) determined 
the AAA prevalence to be significantly higher in men with CAD, 14% versus 3%, 
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but smoking among them was also more common. In a Finnish review study, the 
prevalence of AAA among men with CAD was found to be 9.5% (Hernesniemi et 
al. 2015), and in a screening study, the incidence of AAA was 5.7% in male patients 
with CAD (Vänni et al. 2015). 
3.3 FACTORS INFLUENCING ANEURYSM GROWTH 
3.3.1 Patient characteristics 
The annual growth rate of an aneurysm has been reported to be a mean of 2.2 mm 
according to a meta-analysis by Sweeting et al. (2012) consisting of the results from 
18 studies including 15,475 subjects. The growth rate has been shown to accelerate 
with the size of the aneurysm (Brady et al. 2004) as well as with increasing age (Chang 
et al. 1997). Men may have the higher prevalence of AAAs and present with larger 
aneurysms (Lederle et al. 1997), but women tend to have aneurysms that grow faster. 
In a study by Solberg et al. (2005), the mean growth rates were 2.43 mm for women 
and 1.65 mm for men per year. In this study, the median initial diameter was 31 
mm for women and 34 mm for men, accounting for the lower overall growth rates 
compared to studies with an annual growth rate of 2.6 mm in patients with an initial 
mean diameter of 42–43mm (Brady et al. 2004, Bhak et al. 2015). 
3.3.2 Smoking and hypertension 
Like for the prevalence, active smoking is the most important risk factor also for an-
eurysm growth, with a 0.35–0.5 mm increase in the annual growth rate (Sweeting et 
al. 2012, Bhak et al. 2015). The role of hypertension as the cause of increased growth 
has not been conclusively established (Chang et al. 1997, Brady et al. 2004, Sweeting 
et el. 2012), but according to a recent study by Bhak et al. (2015), it would seem that 
especially elevated diastolic pressure increases aneurysm growth. 
3.3.3 Thrombus formation 
It has been suggested that the proportion of an intraluminal thrombus in the aneurysm 
is associated with growth rate (Behr-Rasmussen et al. 2014). Thrombus location may 
also play a role, for it has been reported that a thrombus in the posterior part of the 
aneurysm is associated with a significantly lower growth rate when compared to an 
anterior location (Metaxa et al. 2015). In a prospective follow-up study on thrombus 
consistency, Nguyen et al. (2014) demonstrated an association between an unorgan-
ised loose thrombus detectable by MRI with faster aneurysm growth. 
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3.4 RUPTURE RISK AND MORTALITY
The risk of aneurysm rupture can easily also be perceived as the risk of death, since 
without intervention, a rupture is affiliated with close to 100% mortality. The rupture 
risk is in concordance with the size of the aneurysm, and according to the ADAM 
trial in the US and the UK Small Aneurysm Trial (1998), an aneurysm smaller than 
55mm carries a rupture risk of 0.6%–1% per year in men and no benefit in terms of 
survival is gained by operating on these smaller aneurysms (Lederle et al. 2002, Powell 
et al. 2007). Women, however, have been reported to have three times the rupture risk 
compared to men (Brown L. et al. 1999). Women also tend to have smaller aneurysms 
at the time of rupture (50±8mm vs. 60±14mm) and a 3.9% risk of rupture at 50mm, 
according to a long-term follow-up report by Brown P. et al. (2003). Of the other 
risk factors, smoking and hypertension have also been associated with higher rupture 
rates (Sweeting et al. 2012).
The decision on operative treatment is based on the risk of rupture and, following 
the findings of the large trials, the criteria used commonly today are an aneurysm 
diameter of at least 55 mm for men and 50mm for women. For the larger aneurysms, 
i.e. aneurysms exceeding the threshold for surgical repair, the risk of rupture has not 
been defined conclusively, for studies are mainly based on mortality data and have 
been conducted on unfit patients excluded from surgical treatment. 
3.4.1 Unfit patients 
In a study on patients considered unfit for AAA surgery, Jones et al. (1998) presented 
the risk of rupture to be 28% within 3 years for aneurysms of 50–59mm and 41% 
for aneurysms larger than 60mm, with a median time of 18 (1–38) months from 
diagnosis to rupture. The conclusion drawn in this study, however, was that unfit 
patients are more likely to die of other illnesses than aneurysm rupture. These other 
illnesses were determined as a cause of death mainly according to the patient records, 
for the autopsy rate was 14.0%.
Conway et al. (2001) concluded in their study that, for unfit patients, a ruptured 
abdominal aortic aneurysm (RAAA) was the cause of death in 36% of the patients, 
an AAA of 55–59 mm being the culprit in 50% of the patients with an AAA of 
60–70 mm and in 55% of the patients with an AAA larger than 70 mm. However, 
the autopsy rate was also low in this study, 15.7%. In a study with a 46% autopsy 
rate, Lederle et al. (2002) demonstrated the 1-year incidence of probable rupture to 
be 9.4% for an AAA of 55–59 mm, 10.2% for an AAA of 60–69 mm and 32.5% for 
an AAA of 70 mm or more. 
3.4.2 Mortality data  
The reliability of mortality data is questionable, for the autopsy rate has declined 
rapidly in recent decades from 50%–80% to 3%–30% in the Western countries (Petri 
1993, Lindström et al 1997, Chariot et al. 2000,Brinkmann et al.2002, Shojania 
et al. 2008). Multiple factors have contributed to this decline. Physicians today are 
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speculated to be less interested in autopsy due to improved antemortem diagnostics, 
even if it has been demonstrated that there is an approximately 10% discrepancy in 
significant findings between antemortem diagnoses and autopsy (Tejerina et al. 2012, 
Liisanatti et al. 2015). Furthermore, for medical autopsies, as opposed to medico-legal 
ones, permission from the family is required and asking for permission after delivering 
the fatal news might be difficult. In the United States, according to Harrington et al. 
(2010), the decline from 50% to 7% in autopsy rate was provoked by the removal of 
the minimum autopsy rate requirement in 1971 and also influenced considerably by 
economic factors. In comparison to other Western countries, Finland is well repre-
sented with an autopsy rate of 25%–30% (Ylijoki-Sorensen et al. 2014).  
3.5 TREATMENT 
3.5.1 Conservative treatment 
For patients who smoke, giving up the habit is the most important form of conservative 
treatment. Mani et al. (2011) demonstrated that a smoking cessation intervention 
cost-effectively increases long-term survival and decreases the need for operative repair 
in patients with small AAAs identified at screening, findings that further encourage 
physicians to promote a non-smoking lifestyle for all AAA patients. 
As for medical management, due to the connection with other cardiovascular 
disorders, the treatment of cardiovascular risk factors as a line of secondary prevention, 
including anti-platelet therapy, antihypertensive medication and lipid-lowering 
medication, is usually commenced, even though convincing data on the reduction 
of cardiovascular events and mortality is lacking according to current literature 
(Robertson et al. 2014).  The effects of these drugs on aneurysm growth and rupture 
rate have been implied but remain to be established, although some evidence exists 
for a reduction of growth rate in patients using low-dose aspirin (Lindholt et al. 2008) 
as well as patients taking statins (Sukhija et al. 2006, Schlösser et al. 2008). For statin 
medication, contradictory findings with no connection to aneurysm growth rate have 
also been reported (Ferguson et al. 2010). According to a Cochrane review on medical 
management of small AAAs, roxithromycin has a small but significant protective 
effect on aneurysm expansion and propanolol a minor insignificant protective effect 
(Rughani et al. 2012). 
3.5.2 Open surgery (OS) 
In open surgical repair, the aneurysmatic part of the aorta is typically replaced with a 
prosthetic graft through a midline incision laparotomy. The alternative is the retroperi-
toneal approach through a left-sided oblique incision (Conway et al. 2015). General 
anaesthesia is required for the operation. Depending on the aneurysmal morphology, 
the aorta is cross-clamped either above or below the renal arteries, a decision crucial to 
renal circulation. Suprarenal clamping is associated with a higher risk of renal failure, 
as demonstrated in a retrospective study on 242 pararenal aneurysm repairs by West 
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et al. (2006) with 22.3% of the patients developing renal insufficiency and 3.7% re-
quiring dialysis. In a study by Wartman et al. (2014) on 69 patients undergoing open 
repair with suprarenal clamping, perioperative renal dysfunction was diagnosed in 
30.4% and 5.8% required dialysis, while late renal dysfunction was found in 17.5%. 
However, infrarenal clamping also affects the kidneys. In a study by Hertzer et al. 
(2002) with 1135 patients undergoing infrarenal repair, renal insufficiency was found 
in 1.7% postoperatively, whereas in a smaller study by Tallgren et al. (2007), acute renal 
dysfunction was discovered in 22% of patients after infrarenal clamping of the aorta, 
with 4% requiring dialysis. The incidence results on post-operative renal function vary 
notably due to diversity in terminology ranging from renal impairment, dysfunction, 
injury and insufficiency to failure, added to alternating definitions of these terms, thus 
complicating the interpretation and comparison of different studies. 
Postoperatively, the patient is monitored in the intensive care unit (ICU) usually 
for 2 days, and the average in-hospital recovery time has been reported to be 7.9–8.8 
days (Schwartze et al. 2009, Huang et al. 2015). Follow-up usually consists of a sin-
gle visit approximately one month after the operation. The European and American 
guidelines, however, recommend ultrasound control at 5-year intervals to detect a 
possible para-anastomotic aneurysm (Chaikof et al. 2009, Moll et al. 2011).
As a late complication, an incisional hernia after midline laparotomy is detected 
relatively frequently after open AAA repair in comparison to aortic repair due to 
aorto-occlusive disease. In a systematic review of seven studies, the incidence of an 
incisional hernia after AAA repair was 21% and after aorto-occlusive repair 9.8% 
(Takagi et al. 2007).
The mortality associated with open AAA repair has remained unchanged. Accord-
ing to a vascular registry study consisting data from 9 different countries (Australia, 
Denmark, Finland, Hungary, Italy, Norway, Sweden, Switzerland and the UK), the 
30-day mortality after elective open repair is 3.5% and after an emergency operation 
due to a ruptured aneurysm 32.6% (Mani et al. 2011). 
3.5.3 Endovascular aortic repair (EVAR) 
In basic EVAR, the aneurysm sac is excluded from circulation with a stent graft typ-
ically extending from the infra-renal aneurysm neck to both common iliac arteries. 
CTA is the imaging method most often used preoperatively, providing information 
on the morphology of the aneurysm and the suitability for EVAR, therefore enabling 
the selection of an appropriately fitting stent graft. The assessment of suitability for 
EVAR is based on the length, diameter and angulation of the aortic neck as well as 
thrombus formation at the proximal sealing site and the tortuosity and diameters of 
the iliac arteries. (Harkin et al. 2007.) According to the instructions for use (IFU), 
49.4% of the infra-renal aneurysms are suitable for basic aorto-bi-iliac EVAR (Krist-
mundsson et al. 2014).
In the procedure, both common femoral arteries (CFA) are cannulated. From one 
side, the main body of the stent graft is introduced into the aorta extending to the 
ipsilateral common iliac artery. The location of the main body in relation to the renal 
arteries as well as aortic and iliac bifurcation is verified with an X-ray using contrast 
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medium. Thereafter, the contralateral limb of the stent graft is introduced from the 
other CFA and additional limbs to the stent graft from both sides if needed. The 
procedure can be performed with local anaesthesia, provided that the patient is co-op-
erative. In a multicentre trial by Broos et al. (2015) with 1261 patients, no difference 
was found in perioperative morbidity and mortality between general, regional and 
local anaesthesia, but the ICU and overall hospital stays were longer among patients 
undergoing general anaesthesia. On the other hand, in the randomised IMPROVE 
trial, the use of local anaesthesia was associated with reduced 30-day mortality com-
pared to general anaesthesia (Powell et al. 2014).
Renal dysfunction may also develop after EVAR as a result of the use of contrast 
medium and the possible interference with renal circulation caused by an unfavourable 
placement of the stent graft. In a meta-analysis consisting of 11 studies with 1974 
patients, clinically relevant renal impairment at one year was found in 18 % of the 
patients (Karthikesalingam et al. 2015).
Post-procedural follow-up in an ICU is not necessary, and the average time spent in 
hospital is approximately 3 days (Schwartze et al. 2009, Huang et al. 2015). Re-inter-
ventions are more common after EVAR than after OR, but they are usually managed 
by endovascular means. In a retrospective analysis of 623 patients undergoing EVAR 
by Johnson et al. (2013), the re-intervention rate was 13%, with a mean follow up 
of 29 months.
Follow-up after EVAR is life-long in order to detect possible endoleaks causing 
continuous aneurysm sac growth, device migration or structural failures. The guide-
lines recommend CTA at 1 and 12 months and, if nothing abnormal is detected, 
ultrasound annually thereafter (Chaikof et al. 2009, Moll et al. 2011). According to 
the Vascunet registry data by Mani et al. (2011), the 30-day mortality for EVAR was 
1.4% after an elective procedure and 19.7% after emergency repair.
3.5.4 Novelties of endovascular treatment 
The newest method in treating infra-renal AAAs, endovascular sealing (EVAS), is, 
according to the IFU, also applicable in shorter and wider necks as compared to 
conventional stent grafts (Karthikesalingam et al. 2013). Sealing of the aneurysm is 
performed with a device consisting of two covered stents with surrounding polyu-
rethane pouches – the aneurysmal sac, i.e. the possible site of endoleaks, is sealed by 
filling these endobags with a polymer solution. So far, promising but only short-term 
results of this technique are available (Carpenter et al 2015).
The basic EVAR and EVAS are designed for infra-renal aneurysms, but with 
evolving materials and techniques, para- and suprarenal aneurysms are today also 
treated with endovascular methods. These include fenestrated (fEVAR) and branched 
(bEVAR) devices as well as the chimney technique, with alternative ways of securing 
the blood supply to the kidneys and visceral organs through either fenestrations in the 
main body of the stent graft or through separate branches. In the treatment of complex 
AAAs, fEVAR and bEVAr have been demonstrated to be useful options with relatively 
low peri-operative morbidity and mortality of 2.4%–6.3% at 30 days. (Wilson et al. 
2013.Glebova et al. 2015, Martin-Gonzalez et al. 2015.) Nevertheless, these methods 
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require expensive custom-made devices (Osman et. al 2015). The attempt to analyse 
the cost-effectiveness of fEVAR and bEVAR in a systematic review setting failed, as 
no clinical trials with unbiased patient selection exist (Armstrong et. al 2014). 
3.5.5 OS vs. EVAR 
Four large randomised trials have been published to date comparing elective OR and 
EVAR: the British EVAR-1 trial, the American OVER trial, the Dutch DREAM trial 
and the French ACE trial (Greenhalgh et al. 2004, Lederle et al. 2009, De Bruin et 
al. 2010, Becquemin et al. 2011). According to these trials, the 30-day mortality has 
been established to be lower with EVAR, but in long-term follow up of a minimum 
of 3 years, no superiority could be established for EVAR (Paravastu et al. 2014). 
Moreover, no significant difference was found in renal function after OR vs. EVAR 
(Brown L. et al. 2010). Epstein et al. (2014) analysed the cost-effectiveness of EVAR 
compared to OR based on these randomised trials without being able to make a 
clear distinction between the two methods; only the OVER trial indicated EVAR as 
more cost-effective. The authors, however, discourage comparisons between countries 
regarding economic issues.
The inclusion criterion for all these randomised trials was an aneurysm suitable 
for both OR and EVAR, but this is rarely the case in reality. The practice has shifted 
towards treating patients with EVAR when possible and with an open procedure when 
EVAR is not an option. Obviously, this policy leads to more complex open surgery 
with fewer capable vascular surgeons, as residents today rarely have the opportunity 
to participate in open abdominal surgery (Aziz et al. 2013).
In the last ten years, EVAR has taken over the position as the first line of treatment 
in many centres worldwide, Helsinki included, due to the clear benefits arising from 
the less strenuous procedure, shorter hospital stay and lower perioperative mortality 
(Kontopodis et al. 2015). That said, the technical aspects as well as the materials and 
equipment required inevitably make EVAR unavailable in smaller centres. European 
guidelines also recommend that only centres with at least 50 elective AAA repairs 
should perform aortic repair to begin with (Moll et al. 2011). Self-evidently, a certain 
number of procedures is needed to acquire the skills in endovascular repair and, in or-
der to sustain these skills, a steady patient flow is also necessary. In Finland, the matter 
of centres with a low volume of AAA procedures was recognised quite early on – in 
1997, a feasibility study conducted after the first EVARs were performed in Finland 
in three university hospitals reached the speculative conclusion that centralisation of 
EVAR would be wise (Lepäntalo et al. 1997). 
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3.6 SCREENING
Since aneurysms are usually asymptomatic and ruptures occur without warning signals, 
leading to a likely fatal result, screening for AAAs has understandably been of interest, 
especially since detecting an AAA by ultrasound is simple and fast with reliable results 
(McGregor 1977, Graham et al.1988). 
Table 3 	 Overview	of	the	randomised	population-based	screening	trials.	Modified	from	
Svensjö	et	al.	2014	with	permission.
In the 1990s, large randomised population screening trials were initiated in the UK, 
Denmark and Australia, with fairly similar prevalence results presented in Table 3 
(Scott et al. 1995, Lindholt et al. 1998, Ashton et al. 2002, Norman et al. 2004).
The benefits expected from the screening programmes included a decrease in 
rupture rate, emergency repairs and aneurysm-related mortality. Screening overall is 
considered to be worthwhile when a level of cost-effectiveness is established, expressed 
in most studies as cost per life year saved. Prior to the publication of results from any 
randomised screening studies, Frame et al. (1993) concluded that screening men 
with ultrasound once between the ages of 60 and 80 years may be cost-effective and 
modestly beneficial. At four years of follow-up, the Multicentre Aneurysm Screening 
Study Group (2002) demonstrated a level of cost-effectiveness defined as at the margin 
of acceptability, whereas Lindholt et al. (2006) concluded, according to the Vyborg 
study, that is seemingly cost-effective with a 75% reduction in emergency procedures 
and a 67% decrease in aneurysm-related mortality. For both studies, the expectation 
was that, during the following years, the level of cost-effectiveness would rise as the 
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cost per life year saved decreases over time, and the Vyborg study group substantiated 
this in a later report with remarkably low incremented cost at 157 € per life year saved 
(Lindholt et al. 2010). In a Cochrane review, the cost-effectiveness of screening was 
recognised based on these four trials, but, at the same time, further analyses were still 
called for (Cosford et al. 2011).
A decline in the prevalence of AAAs due to the general public’s improved, 
non-smoking lifestyle has raised doubts on the benefits of screening programmes. 
Svensjö et al. (2014), however, demonstrated one-time screening for men over 65 
years still to be cost-effective today. Screening programmes are currently in use in the 
UK, USA, Australia, New Zealand, Italy, Sweden, Denmark and Norway (Stather et 
al. 2013). In 2011, the National Institute for Health and Welfare published a report 
by a joined task force investigating the benefit of screening in Finland. The cost-effec-
tiveness was established, but implementing the screening programme would require 
extra resources (Mäklin et al. 2011). 
3.7 TIMING OF ELECTIVE AORTIC REPAIR
Even though the goal is clear – elective aortic repair should take place before the 
aneurysm ruptures – the optimal timing remains unclear. Determining the right timing 
is difficult, for it is based on the estimated risk of rupture mainly derived from studies 
on patients turned down from operative treatment.
3.7.1 Guidelines 
The European Society for Vascular Surgery (ESVS) published clinical practice guide-
lines for the management of AAAs in 2011 (Moll et al.). The timing of elective sur-
gery regarding the whole treatment process is not discussed in the guidelines, but it 
is recommended that a vascular surgeon reviews the patient within 2 weeks of the 
aneurysm reaching 55mm. Preoperative evaluation and treatment of risk factors prior 
to surgery are recommended. Statin treatment is suggested to be started one month 
prior to the operation, a statement perhaps describing the viewpoint on timing.
In North America, the Society for Vascular Surgery (SVS) has published their 
guidelines on the care of patients with a AAA in 2009 (Chaikof et al.). The timing of 
elective surgery is addressed in the guidelines, recognising the necessity of preopera-
tive evaluations as well as the possibility of aneurysm rupture prior to the operation. 
However, no recommendations are declared, except for the inclusion of the patient 
and the family in the process so that they understand and accept the small risk of 
rupture while waiting for the operation. 
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3.8 DELAY IN AAA TREATMENT 
3.8.1 Pre-hospital delay 
AAA formation is usually an asymptomatic process, an a patient-related delay is there-
fore rare. One might be aware of an enlarging pulsating abdominal mass, but for the 
most part, AAA diagnoses are accidental side products of other imaging studies in 
countries like Finland with no active screening programme. When an aneurysm is 
detected by the patient or primary health care professional, referral to the vascular unit, 
is presumably made promptly; however, there is no data to confirm this assumption. 
3.8.2 In-hospital delay
When a patient with a large AAA fulfilling the treatment criteria is diagnosed, the 
planning of the elective treatment begins. The treatment method, open or endovascu-
lar, needs to be determined, a process that may take some time, as can the acquisition 
of custom-made endografts, possible delays in the process that are rarely reported. 
Patients undergoing aortic repair require overall health assessment for the periopera-
tive risks (Moll et. al 2011). Additional investigations and treatment of other illnesses 
may also be required, delaying the AAA repair further. Studies on the delay in aortic 
repair are scarce; Sobolev et al. (2000) reported the waiting times in their institution 
in Ontario, Canada, for all vascular procedures, and even though their aim was to 
treat AAAs within a maximum of 4 weeks, the median time to the operation was 7 
weeks. Oram et al. (2008) reported the results of 54 patients exiting the screening 
programme due to a large aneurysm and for whom elective surgery was considered. 
Eleven patients were excluded from treatment, 3 were operated on an emergency basis 
due to a symptomatic aneurysm, and 2 patients died due to a RAAA while waiting 
for an operation, which took place in a median of 6 months. To date, no reports on 
the delay across the entire treatment process and the repercussions thereof have been 
published.
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AIMS OF THE PRESENT STUDY
The purpose of this study was to explore and analyse the treatment processes of the 
essential patient cohorts in vascular surgery – patients with symptomatic carotid 
stenoses, DFUs or large AAAs. 
The specific aims were to: 
1. Establish the impact of the organisational changes made in 2009 on the delay 
in carotid surgery. (I)
2. Investigate the treatment process of DFUs and define the impact of delay on 
the outcome. (II)
3. Determine the natural course of large AAAs by investigating the patients 
 excluded from operative treatment. (III)
4. Investigate the elective treatment of AAAs and the possible delaying factors 
as well as consequences arising from the delay. (IV)
Aims of the study
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MATERIAL AND METHODS 
Approval for all studies was granted by the Institutional Review Board of Helsinki 
University Hospital (HUH).  
1 PATIENTS AND STUDY DESIGN
The patients and data for this study were retrospectively gathered from the hospi-
tal records. Statistics Finland provided the data on causes of death. The prospective 
HUSVASC registry provided the demographics (Table 4) with specific features for 
each study as follows: 
Table 4		 The	patient	demographics	for	studies	I–IV.	
I 
All 144 consecutive patients with a combined 145 symptomatic carotid stenoses 
undergoing CEA in 2010 were included in the study. The index symptom was cat-
egorised by a neurologist as TIA, AFX, or minor or major stroke according to the 
modified Ranking Scale (mRS). The degree of the carotid stenosis and the possible 
contralateral stenosis were recorded according to the NASCET criteria. The first 
health care contact was determined.
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II
The study population comprised all DFUs (n=273) referred to a vascular surgeon’s 
evaluation during 2010–2011. The demographic data included the patients’ mobility 
and living conditions, previous amputations and revascularisations as well as the 
duration and location of the ulcer.
III
The study comprised all 154 patients with large AAAs who were excluded from 
operative treatment during 2000–2010. The patients were analysed in subgroups 
according to the diameter of the aneurysm: 55–60mm, 61–70mm and >70mm. The 
demographics included pulmonary disease, PAD and malignancy. The evaluation of 
suitability for EVAR was noted. 
IV
In this study, 361 patients assigned for elective AAA repair during 2005–2010 were 
analysed in aneurysm size groups, < 60mm, 61–70mm and >70mm, and also according 
to the treatment method used, OS and EVAR. We determined our success in reaching 
the target times, that were applied in our institution during the study period, from 
the decision on operative treatment to the operation, 1 month for an aneurysm of 
>65mm and 3 months for smaller ones. 
2 DELAY ANALYSIS AND END POINTS 
The delay analysis started from the symptom (I) or referral to a vascular surgeon (II, 
IV). The delays in the various steps of the treatment process were analysed: referral 
delay occurring before the first evaluation by a vascular surgeon, radiological delay 
for the time spent on imaging, the delay in reaching the decision on treatment and 
surgical delay from the decision to the intended treatment. In addition, each study 
had their distinctive features and focuses:
I
The delay analysis included the patient-related delay for the time it took for the pa-
tient to seek medical attention after the index symptom. Perioperative complications 
and the postoperative recovery were determined. Follow-up at 30 days was routinely 
carried out by a vascular nurse over the telephone.
II
The delay analysis was continued after revascularisation in order to include all re-in-
terventions as well as wound healing, one of the main end points of the study. During 
the treatment process, emergency operations were taken into account as were major 
amputations and deaths during the entire follow-up extending until the end of 2013.
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III 
The process of evaluation and exclusion from elective treatment was analysed, includ-
ing the effect of the preoperative clinic established in 2005 and consisting of specialists 
in anaesthesiology and internal medicine. After the exclusion decision, follow-up 
continued until 30 April 2012, during which aneurysm ruptures and deaths were 
noted, focusing on rupture-related deaths. 
IV
In the delay analysis, the time spent on patient assessment in the preoperative clinic 
and other possible instances were also regarded. Emergency repairs and deaths while 
waiting for treatment were the main focuses. Post-operative follow up extended until 
the end of 2012. 
2.1 Statistical analysis
Statistical analyses were performed by SPSS 19.0 (I-III) and MS Excel 2003 (IV). 
Student’s t-test was used in the comparison of the subgroups for continuous variables 
(I, II, IV) and Pearson’s χ test for discrete variables (I). A Cox proportional hazards 
model was employed in multivariate analysis (II) and Kaplan Meier estimate curves 
to determine survival and freedom from RAAA (III). In the delay analysis, the times 
spent on each step of the treatment process were expressed in median days with ranges 
(R) (I,II,IV) and interquartile ranges[IQR] (II,IV). 
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RESULTS
1 SHORTENING THE DELAY FOR PATIENTS WITH 
SYMPTOMATIC STENOSIS (I)
The changes made in 2009, two additional time slots per week in the operating sched-
ule for CEAs and the possibility to assign emergency treatment when an elective 
time was not available, resulted in a significant decrease in delay, with a median time 
reduction from 47 (3–368) to 19 (1–236) days (p<0.001; Figure 1) The changes made 
mostly affected the surgical delay, which decreased from 25 (2–202) to 8 days (0–80). 
Patients (55.2%, n=80) who arrived in HUH on an emergency basis had a median 
delay of 13 (1–148) days from symptom to surgery compared to the 36 (6–326) days 
for patients referred electively.
Figure 1	 The	median	delays	in	2007–2008	and	in	2010.	Reproduced	from	Noronen	et	al.	
2012	with	permission.	
When the patients were operated on changed significantly after the organisational 
changes (Figure 2). Previously, most (68%) patients were operated on in more than 
4 weeks and, in 2010, the same proportion (67%) was treated within 4 weeks. The 
goal of 2 weeks from symptom to surgery was achieved for 37% of the patients in 
comparison to the 11% during the previous study period.
Results




Twenty (13.8%) patients had recurrent symptoms prior to surgery – nine of them 
suffered a TIA, six had AFX and five fluctuating minor stroke symptoms. In addition, 
one patient’s minor stroke progressed into a major stroke. (Table 5) 
Table 5		 The	occurrence	of	recurrent	symptoms	while	waiting	for	CEA	according	to	the	
index	symptom	and	time	after	symptom.	*	One	progression	into	a	major	stroke.
The patients whose surgical delay exceeded 2 weeks (n=32) were investigated 
more closely to discover areas of further improvement in our own work. For nearly 
half (48%) of these patients, no specific reason was found for the prolonged waiting 
time and, on the other hand, for 43% of these patients, there were reasons for the 
delay beyond the surgeons’ influence, such as another illness that required treatment, 
an unexpected staff shortage in the OR and a delay of > 2 weeks at the time of the 
consultation. 
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A closer analysis of the patients (n=21) with the longest delay (> 12 weeks) re-
vealed a substantially longer patient-related delay of a median of 43(0–139) days 
compared to the 0(0–139) days for the entire study population. These patients were 
more often female and their index symptom was more likely to be AFX and not minor 
stroke. The long patient-related delay was also associated with a longer neurological 
and surgical delay of 21(0–81) days and 16(1–80) days, respectively. 
2 THE IMPACT OF DELAY ON DIABETIC FOOT ULCERS (II)
DFUs formed the majority (n=273, 60.5%) of the suspected ischaemic ulcers evalu-
ated in the vascular outpatient clinic by a senior consultant during the study period of 
2010–2011. Cardiovascular manifestations such as coronary disease and hypertension 
were more common, and the use of statins was also more frequent among patients 
with diabetes. (Table 3) 
Revascularisation was planned for 56.0% (n=153) of the diabetic limbs, and 
as primary revascularisation, ET was performed for 85.5% (n=136) and OS for 
14.6%(n=23). An additional 28 diabetic limbs underwent OS due to failed ET, re-
sulting in 67.9%(n=108) endovascular and 32.1% (n =51) open procedures. The 
decision on conservative treatment was made for 44.0% (n=120) of the patients with 
diabetes and was more often based on the expectation of spontaneous healing, whereas 
for patients with no diabetes, their overall condition was more often the reason for 
refraining from revascularisation. (Table 6)
Results




After revascularisation, 84.3% (n=134) of the patients with diabetes were followed, 
as were 77.8% (n=84) of the patients with no diabetes. In a median of 78(16–877) 
days, wound healing was achieved in 61.6 % of the revascularised diabetic limbs, in 
53.7% (n=58) of the patients who received ET and in 78.4% (n=40) of those who 
underwent OS (p=0.003). A conversion of the initial treatment plan from ET to OS 
had no effect on the wound healing rate. For patients with no diabetes, the overall 
wound-healing rate was 43.5%(n=47) – 37.7% (n=29) after ET and 19.4 % (n=6) 
after OS.
At one year from revascularisation, the limb salvage (LS) rate was 86.4% for pa-
tients with diabetes and 79.5% for patients with no diabetes (p=0.053), and the AFS 
was 63.5% and 62.0% (p=0.805), respectively.
The structure of delay, as presented in Figure 3 for all 159 diabetic limbs under-
going revascularisation, did not differ from patients with no diabetes, with a median 
delay from referral to revascularisation of 43(29–66) days. There were 29 urgent 
revascularisations during the treatment process.
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When the delay from referral to surgery was less than 2 weeks, there was no difference 
between patients with diabetes and no diabetes in limb salvage (100% vs. 92.9% at 30 
days, 86.5% vs. 85.1% at 12 months). However, when the delay exceeded 2 weeks, limb 
salvage was significantly (p<0.001) inferior among patients with diabetes (Figure 4). 
In multivariate analysis, diabetes was significantly associated with major amputation 
when the delay exceeded 2 weeks (OR 3.1, 95% CI 1.4–6.9), 
Results




The median follow-up time was 25.9 months ending on 31 December 2013. The 
overall amputation-free-survival (AFS) after revascularisation was 41.5% for patients 
with diabetes and 38.0% for patients with no diabetes (p=0.562). For patients with 
diabetes undergoing OS, the AFS was 45.1%, and for those undergoing ET, 39.8% 
(p=0.528).
3 THE FATE OF THE UNFIT AAA PATIENTS (III) 
The patients who were denied operative treatment consisted of 74 patients with an 
aneurysm of 55–60mm, 57 patients with an aneurysm of 61–70mm and 23 patients 
with an aneurysm of > 70mm. During the study period 2000–2010, the number 
of excluded patients increased, mainly in the category of aneurysms sized 55–70m. 
(Figure 5)
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Over the study period, the preoperative evaluation system changed into a more organ-
ised assessment by the preoperative clinic established in 2005. Prior to that, 37.9% of 
the excluded patients were evaluated by an internist, but the exclusion decision was 
mostly based on a vascular surgeon’s opinion, whereas later 61.6% of the patients 
underwent an evaluation at the preoperative clinic and the decision was reached in 
co-operation with an anaesthesiologist and an internist. The reasons for exclusion are 
presented in Table 7. The suitability for EVAR was analysed for 82.5% of the patients, 
22.3% of whom were found suitable.
After the exclusion decision, the patients were followed until the end of 2012, 
yielding a median follow-up time of 18 months (2 days–6 years and 7 months). Mor-
tality among the study population was high; the overall survival was 22.1%, and the 
larger the aneurysm, the shorter the survival. 
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Table 7 	 The	reasons	for	exclusion	from	operative	care.	Modified	from	Noronen	et	al.	
2013	with	permission.
Of the patients who died during follow-up, 33% died of aneurysm rupture. Across 
the size groups, RAAA was the most common cause, accounting for 42%–44% of 
the deaths (Figure 6). 
Figure 6		 The	causes	of	death	for	the	120	patients	who	died	during	follow-up.	Repro-
duced	from	Noronen	et	al.	2013	with	permission.	
In this study, the overall autopsy rate was 23%. For RAAA deaths, the autopsy rate was 
35%, and 41% of them were confirmed in hospital with ultrasound or CT. (Figure 7) 
Death certificates for the rest of the deceased patients were reviewed and, accordingly, 
the causes of death were classified as either likely to be accurate or not certain. 
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During the median follow-up of 19 months ranging from 2 days to 6 years and 7 
months, 56 (36.4%) aneurysms ruptured. Twelve patients underwent emergency repair 
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4 ANALYSIS OF THE ELECTIVE AAA TREATMENT 
PROCESS (IV)
For the 361 patients with AAAs meeting the treatment criteria, the first visit to the 
vascular outpatient clinic took place in a median of 12 (0–176) days after the referral. 
The treatment decision was made for 26.1% of the patients instantly, and the rest were 
referred to further preoperative evaluations. Evaluations by an anaesthesiologist and 
internist were the most common, the others including a cardiologist’s consultation for 
27.1%. The patients for whom EVAR was planned had more preoperative assessments 
– 44.8% of them had more than 2 assessments, while this was the case for 31.7% of 
the patients assigned to OR. 
The median time from referral to surgery was 101(IQR: 53–159) days for all 
cases, 98(IQR: 52–159) days for OR and 110(IQR: 63–156) days for EVAR. For the 
aneurysm size groups – <60mm, 61-70mm and >70mm – the delays from referral to 
surgery were 112 (IQR: 79–225) days, 91 (IQR:52–119) days and 46 (IQR: 26–65) 
days, respectively. (Figure 9)
Figure 9	 The	cumulative	median	delays	in	2005–2010	for	AAAs	according	to	size.	Modi-
fied	from	Noronen	et	al.	2015	with	permission.
The target time of 1 month from decision on operative treatment to surgery was 
reached for 58% (n=72) of the patients undergoing OS and 45% (n=27) of those 
undergoing EVAR. The 3-month target was achieved for 52% (n=48) and 63 % 
(n=33), respectively. The patients (n=129) exceeding the intended target times were 
analysed more closely. For the majority (77%) of them, no reason for the delay could 
be determined.
There were 11 patients whose aneurysms ruptured during the preoperative period, 
yielding rupture rates of 2.7% (5/187) for aneurysms of < 60mm, 3.5% (3/85) for 
aneurysms of 61–70mm and 5.2% (3/58) for aneurysms of >70mm during a median 
follow-up of 70(38–1190) days (Figure 10). Five patients died of a RAAA without an 
operation, six patients underwent an emergency operation, and two survived the oper-
ation, resulting in 2.5% (9/361) preoperative rupture-related mortality. An emergency 
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operation was also performed for 17 further patients due to a symptomatic aneurysm 
(n=12), an aneurysm diameter of 85–120mm (n=3), acute limb ischaemia (n=1) 
and a suspicious CT finding (n=1). They all survived the emergency operation. The 
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DISCUSSION
LIMITATIONS OF THE STUDY 
Investigating delay in surgical treatment is largely limited by the lack of a possibility to 
engineer a study in prospective settings, for deliberately causing delay or withholding 
treatment from patients threatened by stroke, amputation or death would be highly 
unethical. Hence, all the studies (I–IV) are retrospective with a common goal: to 
learn from the past for the benefit of the future.
Certain additional limitations concerning the study design, data collection and 
outcome analysis are recognised. Patients with symptomatic carotid stenosis undergo-
ing CEA were not compared to patients possibly denied CEA or assigned to BMT, for 
these patients were not considered in the study design (I). Collecting data on ulcers 
and analysing the wound healing retrospectively presents a challenge and, unavoida-
bly, some of this data is missed (II). In the analysis of unfit patients with an AAA, no 
definite exclusion criteria existed and, for most of them, the decision was based on 
multiple co-morbidities (III). In all natural history studies, as in study III, a common 
limitation is the inaccuracy of the causes of death. Death certificates provided the 
information for 56% of the deceased as there were no hospital records or an autopsy 
confirming the diagnosis. Most of these uncertain causes had been documented as 
not aneurysm-related, including six death certificates proclaiming coronary deaths but 
still describing the typical symptoms related to a RAAA. Therefore, the number of 
aneurysm-related deaths might be underestimated, and no conclusions can be drawn 
for the other causes of death.
In the assessment of elective AAA treatment, the conclusions drawn from the 
analysis on reasons for delay are bound to be based partly on speculation since for 
77% of the patients, the reason for delay could not be specified from the patient 
records (IV).  
ESTABLISHING DELAY 
Delay in the treatment of vascular patients can lead to higher morbidity and mortality. 
Therefore, investigating and knowing whether a delay exists is, or at least ought to be, 
of utmost importance in units performing vascular surgery. In order to improve the 
treatment process by decreasing delay, it is necessary to first establish the existence 
of delay.
Discussion
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When this study commenced, a delay had been established for carotid surgery by 
Vikatmaa et al. (2011), but not for patients with DFUs or AAAs. Areas for improve-
ment were discovered for all three patient cohorts. For carotid patients, the delay had 
shortened significantly after the organisational changes made in 2009. The pre-hospital 
delay still played a major role in the delay, even if patients referred to HUH on an 
emergency basis now reached the two-week target time from symptom to surgery 
with a median of 13 days as opposed to the 31 days in the previous report.
For patients with DFUs, the delay from referral to revascularisation was discov-
ered to be too long, with a median of 43 days. The in-hospital delay of 28 days was a 
notable finding, as was the 9 days from referral to first evaluation.
The delay from referral to AAA repair depended on the size of the aneurysm in 
accordance with the risk of rupture. Patients with the largest aneurysms were treated 
the fastest in a reasonable time, but the aneurysms of ≤ 60mm had a fairly long delay, 
with the in-hospital delay constituting most of the delay. 
CAUSES OF DELAY 
Determining the causes behind the delays is a complex task. Patient-related factors have 
been suggested to influence the delay the most (Dombrowski et al. 2015) in carotid 
patients as well as patients with DFUs (Yan et al. 2013), but rarely in the case of large 
AAAs. Patient-related delay is also the most difficult part of the delay to manage, for 
it requires co-operation and motivation from the patient. 
For the in-hospital delay, the causes were fairly similar in carotid surgery and elec-
tive AAA repair (Table 6). 
Table 8	 Reasons	for	the	longest	delays	among	symptomatic	carotid	and	AAA	patients.
The preoperative evaluations for AAAs were not associated with the longest delays, 
contrary to what was somewhat expected as open surgery requires thorough investi-
gation of patient’s overall condition. On the other hand, EVAR may require further 
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analysis of the aneurysmal morphology and sometimes also custom-made devices. For 
most patients, 48% of the carotid and 77% of the AAA patients, no obvious reason for 
the delay could be determined, implying the underlying lack of resources, i.e. operating 
times and also an attitude that the scheduled time was considered satisfactory to the 
patient and the surgeon even if it surpassed the intended target time.
The long in-hospital delay in the treatment of DFUs included approximately 2 
weeks for the imaging and decision-making and nearly 3 weeks from decision to re-
vascularisation. Imaging delay was mainly caused by the limited availability of MRA. 
Like for the majority of the carotid and AAA patients, no specific reason was also 
found for diabetic patients in regard to the waiting time between decision and re-
vascularisation, implying the unavailability of elective times in the operating room 
or angiography suite.  
CONSEQUENCES OF DELAY
The consequences of a delay in the treatment process vary among the vascular patients 
with symptomatic carotid stenosis, DFUs or AAAs. Nevertheless, they all share the 
fear of a grave outcome arising from the delay: stroke for patients with symptomatic 
carotid stenosis, amputation for patients with DFUs and death due to rupture for 
patients with large AAAs.
Of the symptomatic patients with carotid stenosis, 14% had a recurrence or pro-
gression of ischaemic symptoms, including one minor stroke progressing into a major 
stroke, which can be considered as consequences arising from the delay, even if ten of 
them occurred within one week and the median time from symptom to surgery for 
all patients with a recurrence was 11 days. Of the CEAs, 8.3% were performed on 
an emergency basis due to the lack, or suspected lack, of available operating times, a 
figure that would probably have been higher had the surgeons been more meticulous 
in placing patients on the emergency operation waiting list whenever an available time 
within two weeks was not found.
Due to the rapid deterioration of the ischaemic diabetic foot with an ulcer, the 
delay often translates into emergency procedures. Indeed, 12% of our patients were 
assigned in the first visit to emergency revascularisation, reflecting the pre-hospital 
delay, and 6.5% while waiting for elective treatment as a sign of the in-hospital delay. 
There was no difference in limb salvage for patients with diabetes undergoing emer-
gency procedures compared to elective revascularisations, though the small number 
of these patients diminishes the meaning of this finding. One of the original aims of 
study II was to evaluate the success of the intended treatment in relation to the delay. 
However, performing such an evaluation proved too difficult a task and reliable results 
were impossible to obtain mostly due to the heterogeneous presentation of the arterial 
disease and alternating expectations on the revascularisation at the time of the decision. 
Many centres, including ours, advocate the “endovascular first” strategy (Garg et al. 
2014, May et al. 2014, Katib et al. 2015), according to which ET is assigned as the 
first treatment even when success seems unlikely, especially for elderly patients with 
co-morbidities raising the risks involved with open surgery. For patients with DFUs, 
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the ET failure rate resulting in OS was a notable 21%, with no statistically significant 
difference compared to patients with no diabetes.
Delay from referral to revascularisation was associated with inferior limb salvage for 
patients with DFUs (p<0.001), underlining the importance of rapid revascularisation. 
When the delay before revascularisation was less than 2 weeks, including emergency 
procedures, there was no difference in the outcome between patients with and without 
diabetes. The diabetic foot is often compromised by infection and neuropathy, both of 
which potentially contribute to the inferior outcome. In a prolonged delay, the tissue 
lesion and infection may progress silently, whereas without neuropathy, the patient 
usually notices the deterioration and seeks help urgently.
The consequence of delay in the treatment of AAAs may be fatal. During the 
treatment process of large AAAs (IV), there were 11 (3.0%) aneurysm ruptures, three 
before the final decision on treatment and 8 while waiting for the operation. The 
annual risk of rupture varied between 3.0% (95%CI 1.2–6.4%) for the aneurysms of 
<60 mm and 39.7%(95%CI 28.1–52.5%) for the aneurysms of >70 mm, which is in 
line with previous publications (Lederle et al. 2002, Brown et al.2003). The fate of 
patients deemed unfit for elective repair supports this as the overall rupture rate was 
high: 32.4% for aneurysms of 55–60mm, 38.6% for aneurysms of 61–70mm and 
43.5% for aneurysms of >70mm (III). Aneurysm rupture was also the most common 
cause of death in all size groups. Considering the generally low autopsy rates, such 
as the 23% in study III, the achieved 76% accuracy for RAAA mortality can be con-
ceived as a notable accomplishment rarely attained in studies addressing the rupture 
and mortality risk of AAAs.
While waiting for elective AAA repair, 6.4% of the patients underwent an emer-
gency operation, suggesting that the intended schedule for the operation was not 
adequate (IV). Emergency operations for intact as well as ruptured AAAs are associ-
ated with higher perioperative morbidity and mortality (Leo et al. 2005, Mani et al. 
2011), which was confirmed in study IV with 17.4% mortality after an emergency 
operation and 66.7% mortality after a RAAA operation. During the study period, 
EVAR was not routinely performed on an emergency basis in HUH, but today it is the 
method more commonly used and expectations are high on the improved prognosis 
of RAAAs in the future.  
DECREASING DELAY 
In carotid surgery, the changes in our own system resulted in a substantial decrease in 
the in-hospital delay with a median of 19 days from symptom to surgery and 37% of 
patients being operated on within 2 weeks, a result that can be considered commend-
able. Since then, no further follow-up studies have been reported, but the conception 
is that well past 50% of the symptomatic patients with carotid stenosis are currently 
operated within 2 weeks, since if an elective time is not available, the patient is put on 
the waiting list for an emergency operation within 48 hours. Hence, out of all vascular 
emergency procedures, CEA has become one of the most frequently performed. While 
certainly not a favourable outcome, it is, with today’s resources, the only option in 
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order to reach the two-week target time. Challenges can be expected if the aim is set 
on operating even sooner, as has been suggested by the UK National Stroke Strategy 
guidelines with a goal to operate within 48 hours. In the current study, this would 
have prevented 10 of the recurrent or fluctuating symptoms and, possibly, the one 
progression from minor to major stroke occurring on the second day after the index 
symptom. Before we start assigning all symptomatic carotid patients to expedited sur-
gery, the contradictory results of previous reports for (Sharpe et al.2013) and against 
(Stromberg et al. 2012) urgent CEA should be kept in mind. The potential means to 
distinguish the patients at greatest risk for recurrent symptoms and stroke ought to be 
explored, even if the possibilities at present are limited. Perhaps, in the years to come, 
with the aid of risk assessment tools such as the ABCD3 score and novel imaging 
methods, the distinction will become clearer. In addition, to achieve better results 
on operating delays, public awareness needs to be improved, a task unfortunately 
proven difficult (Hodgson et al. 2007). In Finland, campaigning for the recognition 
of cerebrovascular incidents has been launched by the Finnish Brain Association.
For DFUs, the pre-hospital delay also has an important role. Educating patients 
with diabetes on daily check-ups is important, as is foot care by a podiatrist. Whenever 
tissue loss is detected, vascular evaluation by the primary care physician is needed. 
The guideline by the IWGDF to wait 6 weeks of healing assumes that the need for 
urgent care due to ischaemia or an infection is ruled out by primary care measures. 
Underlying ischaemia, however, is not that easily detected due to the insufficient in-
formation provided by the non-invasive methods. (Brownrigg et al. 2015) Therefore, 
6 weeks of waiting seems rather long in the light of the results of the current study 
II. The NICE guideline of evaluation within in 48 hours seems sensible in order to 
initiate the investigations rapidly, for in HUH the median delay from referral to 
first evaluation was a median of 9 days. The imaging mostly relied on MRA, whose 
availability is unfortunately limited, hence the two-week delay between the first visit 
and decision on treatment. If MRA was more accessible, the decision could certainly 
be reached sooner, ideally at the first visit if imaging was scheduled and performed 
according to the referral. An attempt to improve this imaging delay has already been 
made in HUH after the current study period, with 2 time slots a day twice a week 
reserved for MRA the same day as the first visit of ulcer patients with critical limb 
ischaemia. However, these 4 times a week are not even close to covering all patients 
with ischaemic ulcers. Results are yet to be established regarding the effectiveness of 
this reformation, but, unfortunately, the initial perception is that it does not cover 
the patients who benefit from the immediate imaging the most, mostly due to the 
inadequate information in the referrals. DFUs are generally regarded as their own 
entity, and the poor wound healing and prognosis are well recognised according to 
previous studies (Roghi et al. 2001, Söderström et al. 2013). Whenever possible, the 
aim for DFUs has been rapid diagnostics and imaging, and after the results of the 
current study undoubtedly even more so. In 2015 a reception for DFUs by a multi-
disciplinary team including vascular and plastic surgeons, and a diabetologist, have 
been moved from diabetology to vascular surgery in order to increase the number of 
patients reached with this specialised team.
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In the treatment of AAAs, after the results of study IV, we re-assessed the target 
times observed during the study period and set goals for the entire preoperative period 
from referral to surgery: 3 months for aneurysms of <60mm, 2 months for aneurysms 
of 61–70mm and 1 month for aneurysms of 70–90 mm. Aneurysms of >90mm in 
size are operated on an emergency basis. Including the time prior to the final decision 
on operative treatment is important in order to guarantee treatment in a time with 
reasonable risks, for the longer the delay prior to AAA repair, the more likely is rupture 
to occur (III, IV). For the unfit patients, the exclusion from elective AAA treatment 
can be considered as a lethal decision, but for 5 patients in study III, this was not the 
case. At the time of rupture, they survived emergency repair, resulting in a surprising 
41.7% survival rate, comparable to all RAAA operations, even if these patients were 
already considered unfit for elective procedure. Since the study, EVAR has become 
the more common procedure overall, in both elective and emergency settings. The 
perioperative risks are therefore lower, especially when most of the procedures are 
performed under local anaesthesia. The intention is also to make the decision on ab-
staining from operative treatment jointly with the different specialists and the patient. 
DELAY IN THE FUTURE 
The prevalence of vascular disorders such as carotid stenosis, peripheral arterial disease 
and aortic aneurysms all increase with age, as does the prevalence of diabetes. The 
diagnostics are also constantly evolving, leading to more patients being diagnosed. In-
evitably, we will have more patients to treat. The resources for treatment, however, are 
not likely to proliferate at the same pace. Therefore, prioritising and patient selection 
will become necessary. Both are tedious tasks, but should already be considered today.
Prioritising should be primarily conducted within the patient cohorts with the 
following goals in mind: Distinguishing the carotid patients at the highest risk of 
recurrent symptoms and stroke, prioritising the patients with diabetes in diagnostics 
and treatment amongst patients with limb ischaemia and tissue loss, and, for AAA 
patients, ensuring that operating dates are assigned according to the size of the 
aneurysm, waiting time included.
Prioritising is strongly linked with the timing of treatment. Deciding who needs 
to be treated first requires the comprehension of optimal timing for each patient. 
According to the current thesis, the optimal times to treat the patients being discussed 
are: 2 weeks from the symptom for patients with symptomatic carotid stenosis, 2 
weeks from the first visit for patents with DFUs and 1–3 months from referral for 
patients with large AAAs.
When deciding on the order patients are treated in, ideally only patients requiring 
the same procedure are compared. Seldom does anything constructive arise from 
comparing CEA to lower limb bypass, i.e. debating on whether a patient who had 
a TIA a week ago or one with a DFU should be operated first, nor is the decision 
based on evidence. Unfortunately, the described situation is where we currently, but 
hopefully not permanently, often find ourselves in when faced with the mounting 
emergency operating lists due to the lack of available elective times. In such a situ-
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ation, the decision is reached by considering the disease-specific aspects as well as 
the patient’s condition and capacity to wait. For all patients, it is also important to 
consider the treatment altogether, mainly when the overall condition of the patient 
is severely compromised. The sometimes difficult but best decision for the patient is 
to withhold surgical treatment. The complexity of this decision is well-described by 
the old proverb,  “Good surgeons know how to operate, better ones when to operate, 
and the best when not to operate.” 
The importance of timing for three major patient cohorts in vascular surgery is 
established in the current thesis. As a noteworthy observation, the timing of vascular 
procedures is demonstrated to depend on several matters, starting with the patient 
and the caring physician, but also ranging from the availability of diagnostics and 
reception times at the outpatient clinic to the capacity in the operating room and the 
ward. Furthermore, an important conclusion arising from this thesis is the vascular 
surgeons’ limited power to decrease the delay alone. Communication and collab-
oration between specialities involved in the patient’s care in order to manage the 
in-hospital delay is fundamental. And lest we forget, the timing of treatment is not 
the only thing affecting the patient’s outcome. The patient’s pre-existing condition 
and the professional skills of the personnel at each step of the treatment process are 
all as important. Therefore, timing is not everything, but it is a vital thing.  
Discussion
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CONCLUSIONS
1. In-hospital reforms facilitate decreasing the delay for patients with symptomatic 
carotid stenosis. Emergency evaluation leads to the best results, and minimising 
the pre-hospital delay is therefore required to meet the current guidelines.
2. For patients with DFUs, revascularisation should be organised rapidly once 
ischaemia is confirmed, preferably within two weeks. 
3. Aneurysm rupture is a significant cause of death among patients determined 
unfit for surgery regardless of the size of the aneurysm.
4. Establishing guidelines for the timing of elective AAA repair is important, 
as is evaluating the fulfilment of these guidelines in order to avoid aneurysm 
ruptures while waiting for treatment. 
Conclusions
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